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Summary of Key Points 
 
Background and context  
 
• Internationally, there is growing recognition of the harms that punitive 
drug policies cause, and a movement towards harm minimization and 
health efforts instead of traditional criminalization, law enforcement 
and abstinence based responses. 
 
• There is a commitment in Scotland to reduce drug harms and the 
alarming recent growth of drug related deaths. However, the justice 
system’s ability to reorient its approach towards people who use 
drugs is constrained by the current UK law, notwithstanding recent 
developments elsewhere in the UK, which illustrate the potential for 
localised innovation.  
 
• This paper gives an overview of seven case studies in drug law 
reform approaches from five countries. It aims to support Scottish 
Government research and policy development regarding drug law 
and enforcement, and the work of the Drug Deaths Taskforce in 
identifying successful interventions and locating them within their 
legal and policing contexts. 
 




• Most drugs do not inherently cause large amounts of harm in and of 
themselves when used casually. Rather, the vast majority of drug 
harm arises from dependence.  
 
• The hierarchy of harm is not well represented in most counties’ 
classification laws. Data on harms in the UK make it clear that the 
present UK drug classification system does not correspond with the 
harm each substance causes.  
 
• In particular, ecstasy and LSD are consistently ranked as two of the 
lowest harm drugs, despite being Class A drugs in most jurisdictions. 
Cannabis is also consistently ranked as less harmful than alcohol or 
tobacco, which are legal in most jurisdictions.  
 
Risk Environment  
 
• How the law is implemented and enforced can significantly impact the 
effectiveness of interventions.  
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• The risk environment can be thought of in terms of the physical, 
social, economic and policy contexts in which people use drugs. Both 
practical policing decisions (such as physical patrols), and 
bureaucratic structures (such as inter-agency referral pathways) can 
significantly influence people’s decisions about drug use and service 
engagement, and public health outcomes.  
 
What doesn’t work? 
• There is an emerging consensus that ineffective interventions for 
people who use drugs tend to be ones that:   
o are excessively punitive or involve excessively close 
monitoring  
o do not involve a rehabilitative element or build skills for the 
future 
o reinforce criminal identity  
o are implemented poorly  
 
• a common failure of many interventions, whether psychoeducational, 
control-oriented or deterrence-oriented, is a failure to help people to 
gain the skills they need to manage situations differently in the future.  
 
Case Studies  
 
Seven case studies were selected for closer examination in this paper. The 
case studies were not selected systematically, but on the basis of 





• The dominant strategy in Australia for many decades has been a 
policy of criminalising the use and supply of illicit drugs.  
 
• Research on major policing crackdowns in Australia have generally 
found that such operations tend to make only modest impacts on 
supply and overall exacerbate harms rather than reduce them, by 
pushing drug use into more dangerous places, and more dangerous 
transport and consumption methods.  
  
• In recent years, some reforms have occurred including:  
o Legal decriminalisation of cannabis possession in some States 
and Territories, replacing criminal sanctions with civil fines.  
o In other states, de facto reforms have taken place. These 
generally involve interventions such as diversionary cautions or 
referral to treatment. However, these schemes have strict 
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eligibility criteria which can exclude those who may need them 
most.  
o In some places, police have supported harm minimisation 
interventions by, for example, limiting unwarranted patrols near 
needle exchanges.  
 
• Evaluation of cannabis expiation schemes show some 
implementation problems, but have been effective at reducing 
enforcement costs without increasing consumption.  
 
• Research has indicated that drug use in Australia is relatively stable 
over time and cannabis decriminalisation has not increased 
consumption. However, despite this, the number of civil penalties 
issued has continued to increase, suggesting that police propensity to 
detect and formally process cannabis possession may have 
increased due to the lower stakes of the civil penalty – an effect 




• Canada has allowed medically prescribed cannabis since 2001, and 
in 2018 changed the law to create a fully legal, regulated market for 
recreational use.  
 
• Retail cannabis is now available in all Canadian jurisdictions, with 
some states using government operated retailers and others using 
licensed private providers  
 
• This change was motivated by a desire to not just decriminalise 
cannabis consumers, but to also remove production and revenue 
from criminal enterprise, giving the government both control over 
quality assurance, and the ability to collect tax on this previously 
black market.  
 
• It is too early to confidently assess the change’s impact, however the 
data available suggest that:  
o After a small initial rise, reported consumption returned to pre-
reform rates and has been relatively stable since.  
o Canadians report accessing significantly less cannabis directly 
from the illegal market.  
 
• Vacouver also serves as an informative case study on harm 
minimisation for harder drugs. In 2003, Vancouver opened North 
America’s first supervised injection facility. It initially operated under a 
special exemption from Canada’s drug laws, and its legal status was 
affirmed by the Canadian Supreme Court in 2010.  
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• Vancouver police have adopted an organisation-wide policy that 
treats drug use as a public health issue and encourages police to use 
discretion and refer them to the safe injecting facility or other 
services. 
 
• Since it began, there has never been a death at Vancouver’s 
supervised injection facility. Extensive evaluation has indicated that 
the facility decreases risk of fatal overdose, improves service users’ 
safe injecting practices, increases uptake of addiction treatment, and 
reduces public nuisance issues.  
 
• There is also evidence that relationships between drug users and 
police have improved, police now regularly refer people to the safe 
injecting facility, and are more likely to view people who use drugs as 
needing protection.  
 
• The supervised injecting facility has also served as an important first 
step for building further innovation, such as current work on heroin 





• Since a law change in 2011, Denmark now has five supervised Drug 
Consumption Rooms (DCRs) across three municipalities.  
 
• Overdose deaths in Denmark have been falling since consumption 
rooms were introduced. Evaluations indicate that DCR’s have 
contributed to reducing the number of overdose deaths in the cities 
that have them. There is also evidence from the Copenhagen facility 
that crime, violence and publicly discarded syringes have all 
decreased in the area.  
 
• Research has highlighted the important role consumption rooms have 
played in helping people access health, social and addiction services.  
 
• Research on police attitudes also suggests that the advent of  
decriminalization zones around consumption rooms has caused more 
police to view drug users as people in need of police protection rather 




• Cannabis has been decriminalised for personal use since 1971. The 
current day ‘coffee shop’ model has developed through a dialogue 




• Today, coffee shops may sell cannabis as long as they are licensed 
and adhere to a range of regulations, including limits on the volume 
that can be traded, a minimum age of 18, and not selling alcohol or 
contributing to public nuisance.  
 
• The consumer side of this model has been largely successful, and 
cannabis use in the Netherlands is about average for Europe despite 
its laws being significantly more liberal than most.  
 
• However, because the law only permits and regulates small scale, 
consumer transactions, the cultivation and wholesale supply to coffee 
shops remains unregulated and criminal enterprise is significantly 
involved.  
 
• For harder drugs, the Netherlands has developed a comprehensive 
health-based harm minimisation approach, with many of their most 
notable policy developments arising from informal or experimental 
practices that were subsequently codified by the government. Needle 
exchanges, safe injecting facilities and heroin assisted treatment are 
all examples of this.  
• Research on the impact of a period of intensive policing crackdowns 
in the 1990s has consistently shown that such enforcement 
crackdowns contributed to moving drug scenes outdoors and into 
suburbs, increasing both the number of people involved and the 
degree of risk they faced.  
 
• The Netherlands has very low rates of problematic drug use, and 
arrests for minor possession are extremely rare. Drug users in the 
Netherlands also tend to use safer practices (for example, a very low 
proportion of opiate users inject), and this has led to relatively high 
survival rates and longer life expectancy for people who use heroin in 
the Netherlands.  
 
• Due to substantial investment in sheltered housing, integrated drug 
treatment, public mental health care, services for the homeless and 
criminal justice interventions, most problematic drug users now live in 




• In 2001 Portugal decriminalised the purchase, possession and use of 
all illicit drugs. The change went beyond depenalisation, which 
removes custodial sentencing, but did not amount to full legalisation, 
as the production, manufacture and large-scale distribution of illicit 
drugs remain a criminal offence. 
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• Low-level offenders are now dealt with administratively by informal 
“dissuasion commissions”. People found to suffer from addiction 
typically receive a suspended penalty in order to allow them to seek 
treatment. The commission may also impose fines or various 
personal restrictions on people’s drug use.  
 
• The implementation of this model is supported by investment in a 
systematic approach to treatment, harm reduction and social 
reintegration across the country.  
 
• Studies have generally found that the change did not significantly 
increase consumption or decrease drug prices. Moreover, research 
estimated that decriminalisation has decreased the social costs of 
drug use by 18%. 
 
• Initially, decriminalisation had a clear direct impact on prison 
populations in Portugal, with substantially drops in the prison 
population and fewer incarcerated people reporting drug use. 
Incarceration rates began to rise again in 2008, although the profile of 
incarcerated offenders is now different and it is likely other external 
trends contributed to this. 
 
• There is some evidence of “net-widening, similar to that seen in 
Australia, leading to increasingly low level offenders being brought 
before commissions. This is an important implementation lesson in 
ensuring laws are explicitly designed to prevent mission creep.  
 
Key themes from the international literature 
 
• Research on drug criminalisation generally indicates that criminal 
sanctions for drug use or possession tend to exacerbate harm or 
undermine efforts at harm minimisation, particularly around safe 
injecting and treatment access.  
 
• Major policing crackdowns and enforcement operations tend to 
increase harms to people who use drugs. Research from a number of 
countries has shown that crackdowns are more likely to move drug 
dealing and usage geographically than to reduce them, incentivise 
more unsafe transport practices, and discourage people from 
carrying clean injecting equipment.  
 
• Incarceration is associated with increased risk of drug death after 
release, while decriminalisation is associated with improved social 
integration and employment.  
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• Decriminalisation has also been shown to reduce the strain on justice 
systems.  
 
• A large proportion of drug revenue is reinvested in other organised 
crime activities such as extortion, fraud, pornography, illegal 
poaching and weapons trafficking. Creating legitimate drug markets 
can help to divert income that perpetuates other crimes.  
 
• Moreover, research indicates that decriminalisation does not lead to 
significant increases in drug use or other crimes.   
 
• A growing number of countries have implemented supervised 
injecting facilities or drug consumption rooms. Such interventions 
have consistently been shown to:  
o Provide care in instances of overdose, preventing them from 
becoming fatal.  
o Improve service users’ knowledge and practice of safe injecting 
practices.  
o Improve uptake of addiction treatment.  
o Provide healthcare for other issues, particularly injection-
related infections, to drug users who may otherwise not access 
mainstream clinics.  
 
• Research on cannabis decriminalisation consistently finds that 
decriminalisation does not significantly increase demand or 
consumption, but there is some evidence that liberalising cannabis 
laws causes some people to substitute away from higher harm drugs 
such as opioids or alcohol.  
 
• In general, cannabis decriminalisation provides an opportunity to 
divert people away from the harms of the justice system. However, 
there is some evidence that making low level drug offence processing 
easier creates a “net-widening” effect that catches more people who 
might otherwise have benefited from police discretion. This pitfall 
should be guarded against in the design of any decriminalisation 
approach.  
 
• Fully legal cannabis markets can be implemented and regulated in a 
number of different ways to reduce illegal trafficking and drug 
revenue supporting other criminal activities.  
 
• Decriminalisation, diversion schemes, and the limited instances of 
legalisation suggest that similar benefits can be found for “harder” 
drugs than cannabis. Punitive enforcement is associated with 
increased crime, while less punitive approaches like diversion are 





1. Purpose and context 
 
 
This paper gives an overview of seven case studies in drug law reform 
approaches from five countries. It aims to support Scottish Government 
research and policy development regarding drug law and enforcement, and 
the work of the Drug Deaths Taskforce in identifying successful interventions 
and locating them within their legal and policing contexts. This is a research 
paper and represents the findings of the project only. It does not constitute a 
Scottish Government policy position.  
 
Internationally, there is a growing recognition of the harms that punitive 
drug policies cause, and a movement towards harm minimisation 
efforts instead of traditional enforcement and abstinence based 
responses to drugs in the community. Reforms such as depenalization, 
decriminalization and even regulated legalization are increasingly common 
internationally, as are efforts to ensure policing and health priorities are better 
aligned. As Palmer noted in 2018: “during a period of arguably the most 
stringent prohibitionist enforcement in history, worldwide drug production has 
increased, drug consumption has increased, the number of new kinds of 
drugs has increased, drugs remain readily available to the consumer market, 
drug prices have decreased and the purity of street drugs has increased. If 
this is a recipe for success it is difficult to envisage a recipe for failure.” 
(Palmer 2018) 
 
In Scotland, drug law is governed by the UK Misuse of Drugs Act 1971. 
There is a continuing commitment in Scotland to reduce drug harm, including 
addressing the rising number of drug related deaths. This has involved police 
engagement in harm reduction approaches, but the justice system’s ability to 
reorient it’s approach to people who use drugs is constrained within the 
current law.  
 
The relationship between people who use drugs and the health and 
justice systems is complicated. Research from 2016 showed that 77% of 
people who died from overdose in Scotland had been in drug treatment, 
prison or police custody, or discharged from hospital in the six months prior 
to death (Barnsdale, 2018). Police officers are present at the scene of most 
overdoses (both fatal and non-fatal) if the emergency services are called, 
although the true number of non-fatal overdoses in Scotland is not known. 
 
Moreover, commonly quoted drug death figures relate only to 
overdoses, not including other deaths related to drug use. Many of the 
wider harms of drug use are not measurable, but the overall extent of health 
harms and early death are indicated in Scottish Burden of Disease study, 
which showed that drug use disorder was the eighth most common cause of 
disease burden in Scotland in 2016. Of this burden, 60% was due to 
premature mortality and 40% to health loss caused by drug use disorders 
(NHS Health Scotland, 2016).  
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Drug treatment has been found to reduce costs. Research from 2010, 
found that the total social and economic cost of illicit drug use in Scotland is 
just under £3.56 billion (around £61,000 per problem drug user) per annum. 
Estimated costs of crime are reduced significantly for individuals in treatment 
(from £12,713 for individuals with no intervention in place; to £1,536 for those 
in treatment for more than one year) (Malloch, 2011). 
 
In November 2019, the Scottish Affairs Committee made a number of 
recommendations including that the Misuse of Drugs Act be amended 
to allow a range of public health focused responses, and that the UK 
Government should move away from treating drugs as a Criminal 
Justice matter (House of Commons Scottish Affairs Committee, 2019). 
Similarly, The UK Parliament Health and Social Care Committee inquiry into 
drug use called for radical change to the drug policy and decriminalisation for 
the possession of small amounts of drugs for personal use (House of 
Commons Health and Social Care Committee, 2019). 
 
The Scottish Government has now established the Drug Deaths 
Taskforce, in response to the almost unparalleled rise in annual 
overdose deaths in recent years. The Taskforce is examining the main 
causes of drug deaths, and will advise what changes, in practice or in the 
law, could help save lives. They are also considering the impact of the 
Misuse of Drugs Act on taking a public health approach to the drug deaths 
emergency, including proposals to provide harm reduction services, such as 
medically supervised overdose prevention rooms. 
 
There are some examples of elsewhere in the UK where justice 
agencies are working with harm reduction services, although again 
these are all bounded by the Misuse of Drugs Act.  
 
o As far back as 1988, a Police Order in England and Wales made it 
service policy that people who inject drugs should not be arrested 
for carrying injecting equipment in a public place (Monaghan & 
Bewley-Taylor, 2013). 
 
o The Checkpoint scheme in Durham, England diverts certain people, 
including those with possession or minor dealing charges, into a 
four month long offender management programme with a navigator 
and support tailored to the individual, instead of prosecution. It has 
shown lower reoffending rates for those diverted from prosecution 
into rehabilitation.  
 
o A pilot of the UK’s first drug safety testing service at a music 
festival, involving a police negotiated ‘tolerance zone’ around the 
service in a large fixed tent in the festival’s welfare area, took place 
in 2018 with paramedic and support services (Measham, 2019).  
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o Various naloxone pilots across the four nations of the UK.  
 
With this context in mind, the remainder of this paper focuses on the 
international evidence. The next section lays out some frameworks for 
considering different options – the role harm plays in policy calculus, and the 
impact law and enforcement has on the risk environment for those who use 
drugs, and what is known about policies that don’t work. The subsequent 
section provides case studies on reforms made in Australia, Canada, 
Denmark, The Netherlands and Portugal, and highlights some other 
international examples of note. The final section summarises key themes 
from the international literature, relating to criminalisation and harm 
reduction, supervised consumption rooms, cannabis-specific reforms, 





2. Frameworks for considering law reform 
 
‘The policing of drug markets is usually conceptualised primarily as a matter 
of law enforcement – drug dealers and people who use drugs are breaking 
the law, and the role of the police is to reduce such law breaking. However, 
the wider purpose of policing is to ensure the safety of the community by 
reducing harms to its members’ (Stevens, 2013). 
 
2.1 The case for considering change 
  
• There is much to be done to reduce drug harms in Scotland, but there are 
limits on how radically practice can change without changing the legislative 
framework. While regulation can be imperfect at achieving its objectives, the 
government has a wide range of policy options at its disposal which can be 
used to help mitigate risks outside of the criminal law. 
 
• There is no strong link between harsh penalties and the prevalence of 
drug use. One might expect that countries that have the toughest penalties 
for drug use would also have the lowest levels of drug use. However, there is 
no obvious relationship between how prevalent drug use is and how 
aggressively the criminal law and other regulatory policies are applied. A 
study of the global prevalence of common recreational drugs concluded: 
“Globally, drug use is not distributed evenly and is not simply related to drug 
policy, since countries with stringent user-level illegal drug policies did not 
have lower levels of use than countries with liberal ones” (Degenhardt, 2008).  
 
• Some jurisdictions have created fully legal, regulated markets for some 
drugs, although this is a relatively recent approach and there are only a 
small number of examples so far. 
 
• More common are jurisdictions that have undertaken some kind of 
decriminalisation, the main options being: 
 
o Removal of use/possession from criminal law, irrespective of the 
amount possessed. This may be with a civil sanction or no action at 
all (a civil sanction might apply, for example, when a place of use 
restriction is breached, such as use in a public park).    
 
o Removal of use/possession from criminal law up to a certain 
threshold amount.    
 
o Removal of criminal penalties for eligible people or offences, up to a 




o Change in practice, without removal from the criminal law (de facto 
decriminalisation), although this raises issues in relation to the rule 
of law and potential bias in application.  
 
• However, these less ambitious reforms, such as instituting fines and 
other civil penalties, do not remove all of the costs associated with 
criminalisation:  
 
o Even if characterised as noncriminal sanctions, civil fines and the 
associated administrative process can have significant punitive 
effects, which may be indistinguishable from the effects of court-
imposed fines for criminal offences (Quilter & McNamara, 2019).  
 
o Reducing penalties for illicit drugs may result in net-widening if the 
lower threshold makes it more likely police will formally process 
people who may otherwise have benefited from discretion, as has 
been seen in parts of Australia. In the United Kingdom, when 
cannabis was reclassified as a lower-class drug and police were 
advised to warn and confiscate rather than arrest users, the number 
of convictions fell initially, but eventually returned to previous levels 
and the overall number of drug possession offences increased 
sharply with more formal warnings (Bryan, Del Bono, & Pudney, 
2011).  
 
2.2 Harms  
 
 
In setting policy goals, it is important to consider the magnitude and 
distribution of drug harms. Different drugs have different usage patterns and 
different impacts on people who use them, and (although all drugs are used in all 





• Most drugs do not inherently cause large amounts of harm when used 
casually. Rather, the vast majority of harm arises from dependence.  
  
• The hierarchy of harm is not well represented in most counties’ 
classification laws – for example ecstasy and LSD are consistently ranked 
as two of the lowest harm drugs, but are class A drugs in most places.  
 
• On the basis of data on harms in the UK, it is clear that the present UK 
drug classification system is not directly based on the harm each 
substance causes.  
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• An illicit drug harm index developed for the New Zealand Ministry of Health 
estimated that the harms per drug user between casual and dependent 
users, and between substances, differ significantly (McFadden Consultancy, 
2016). They considered individual harm through disability/death, and social 
harms including drug related violence, property crime, organised crime 
reinvestment in other crimes, harms to family and friends, tax avoidance, and 
legal/social intervention costs. The chart below shows their estimates of harm 
per casual user and per dependent user. It shows that: 
 
o Most drugs do not inherently cause large amounts of harm when 
used casually. Rather, the vast majority of harm arises from 
dependence.   
 
o The hierarchy of harm is not well represented in most counties’ 
classification laws – for example ecstasy and LSD are the two 
lowest harm drugs, but are typically class A drugs in most places.  
 
Other studies also consistently rank the relative harms of ecstasy and 
cannabis as lower than that of legal drugs (alcohol and tobacco) and other 
illicit drugs (such as heroin and cocaine) (for example: (Bonomo, et al., 2019) 





• A British study in 2010 analysed data from a multicriteria decision analysis 
conference on drug harms. The harms were assessed according to a set of 
17 
16 criteria developed by the Advisory Council on the Misuse of Drugs (Nutt, 
King, & Phillips, 2010). The harms assessed were:  
 
Harms to users  Harms to others  
▪ Drug-specific mortality  
▪ Drug-related mortality 




impairment of mental 
function 
▪ Loss of tangibles 
▪ Loss of relationships 
▪ Physical or psychological injury 
▪ Crime  
▪ Environmental damage  
▪ Family adversities 
▪ International damage 
▪ Economic cost 
▪ Community 
  
o Weighted scores provided ratings on harm to the individual, harm to 
society, and an overall harm score. These findings lend support to 
earlier work from both UK and Dutch expert committees on assessing 
drug harms. It concluded that “on the basis of these data it is clear 
that the present UK drug classification system is not simply 
based on considerations of harm.” The final ratings for all drugs 




• The economic harms of inefficient policies should also be considered. 
Research by Transform Drug Policy Foundation (Rolles, 2009) considered 
four hypothetical scenarios, and estimated the benefits bringing all drugs in 
England and Wales under formal regulation. Their estimates for different 
scenarios are laid out below (estimates for FY 2003/4):  
 
Change in number of 
drug users  
Estimated benefits from regulation of all 
drugs in England and Wales, compared to 
prohibition  
Decrease by 50%  £13.9 billion 
No Change  £10.8 billion 
Increase 50%  £7.7 billion 
Increase 100% £4.6 billion  
 




2.3 Risk environment  
 
 
In addition to more accurately conceptualising drug use harms, the breadth of the 
law’s implications (both intended and unintended) must be considered in terms of 
its contribution to the environment in which people view, buy and use drugs. The 
table below shows an example of the factors that influence the HIV risk 





o How the law is implemented and enforced can significantly impact the 
effectiveness of interventions.  
 
o The risk environment for people who use drugs is influenced by many 
factors. Both practical policing decisions (such as physical patrols) and 
bureaucratic structures (such as inter-agency referral pathways) can 





Stevens et al note that “The outcomes of diversion will depend on relationships 
between policing systems and other agencies as well as the capacity of healthcare 
and welfare systems to provide effective treatment and to support social 
integration” (Price, Parkes, & Malloch, 2020). 
 
The Ontario Treatment Network have written about the importance of appropriate 
policing responses in balancing the risk environment for drug users: “while macro- 
and meso-level laws and policies are intended to guide policing responses to drug 
and injection equipment possession and use, they do not necessarily align with 
policing behaviour enforced on the streets. Engaging police in harm reduction 
strategies may provide an opportunity to reduce the injection drug-associated 
harms while also reducing crime” (Rapid Response Service, 2016)  
 
How the law is implemented and enforced can significantly impact the effectiveness 
of interventions. Ontario treatment network’s paper on engaging law enforcement in 
harm reduction programs for people who inject drugs found evidence to support the 
conclusions that:  
 
• Policing practices can hinder injection drug users’ access to sterile 
syringes  
 
• Police targeting people who inject drugs can increase unsafe injecting 
behaviour 
 




• Members of minority groups who inject drugs can be unequally 
targeted in enforcement.  
 
• Harm reduction can be supported by:  
 
o collaboration between the law enforcement and public health sectors; 
 
o encouraging police discretion with the law in encounters with people 
who inject drugs;  
 
o providing comprehensive harm reduction training for police officers;  
 
o limiting police presence surrounding harm reduction and health 
services used by people who inject drugs. 
 
Public policy may be oriented towards harm reduction, and individual-level services 
may be available – but the legal framework and the police who enforce it have 
substantial power to either encourage or deter their successful engagement.  
 
2.4 What doesn’t work  
 
An ideal legal framework should create harmony rather than tension between 
the obligations and incentives law enforcement face, and those faced by 
health and social care providers. Where there is tension between legal 
enforcement and evidence-based interventions, substantial resource can be wasted 
on ineffective treatments, services that are never accessed by those who need 




• The specific study of ineffective interventions and what doesn’t work to 
reduce harms is a relatively new field, but a consensus is emerging that 
ineffective interventions tend to be ones that:  
  
o are excessively punitive or involve excessively close monitoring  
 
o do not involve a rehabilitative element or build skills for the future 
 
o reinforce criminal identity  
 
o are implemented poorly  
 
• A common failure of many interventions, whether psychoeducational, 
control oriented or deterrence-oriented, is a failure to help people to gain 
the skills they need to manage situations differently in the future. 
21 
harm. With that in mind, considering what does not work for those with drug 
dependency in the justice system is as important as what does work.  
 
The field of specifically studying ineffective interventions is still young, but a number 
of quality review papers have begun to identify some of their common features:   
 
• Interventions that are excessively punitive or involve excessively close 
monitoring are likely to be ineffective 
 
o MacKenzie and Farrington’s (2015) and Lipsey and Cullen’s (2007) 
systematic reviews both concluded that effective interventions for 
reducing reoffending were those that are rehabilitative and skills 
building (e.g., drug treatment and cognitive skills programs), while 
ineffective interventions were, on average, characterized by 
surveillance and control, including prison sentences, boot camps, and 
intensive community supervision. 
 
o Barnett and Howard (2018) review 21 systematic reviews on effective 
interventions for those either in prison or serving sentences in the 
community. It concluded that for those monitored in the community, 
increased supervision or surveillance without rehabilitative support 
may be ineffective. The authors note that neither ignition interlock 
interventions (for drink-driving) nor regular drug testing had any impact 
on recidivism as stand-alone strategies - consistent with a number of 
other rigorous evaluations of intensive supervision, surveillance and 
control based strategies, which have generally been unlikely to have a 
positive impact on reoffending for young adults or adults (Lipsey, 2009) 
(MacKenzie & Farrington, 2015).  
 
o Koehler et al’s (2014) meta-analysis included three robust studies of  
drug testing orders, involving regular urine testing and increasing the 
likelihood of detecting use (two programmes included some form of 
psychosocial care as well). Analysis showed no significant effect on 
crime or substance abuse by participants, although the authors also 
noted that there may be some deterrent effect for specific sub-groups, 
for example, people whose drug use is less entrenched. 
 
o There is, broadly, a strong evidence base for the effectiveness of 
Opioid Maintenance Therapy (OMT) in reducing heroin use, drug 
injecting and drug driven crime. However, meta-analysis looking 
specifically at prison-based OMT for substance misuse, showed that 
although receiving OMT in prison did reduce illicit opiate use, findings 
on criminal recidivism were mixed, and studies reporting a positive 
impact on reoffending found that benefits were lost within 6 months 
(Hedrich, et al., 2011).  
 
• Interventions that do not involve a rehabilitative element, or do not 
build skills for the future are likely to be ineffective 
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o Prendergast et al’s (2013) meta-analysis of international drug 
treatment found that interventions that do not adhere to Risk-Need-
Responsivity (RNR) principles (i.e., did not match level of treatment to 
level of risk of reoffending, did not target factors known to be 
associated with crime, and did not use multimodal, cognitive-
behavioural approaches to treatment) were less effective in reducing 
reoffending, than those adhering to these principles. The authors 
concluded that, in general, drug treatment programs have a greater 
impact on drug outcomes than crime outcomes, but that the application 
of RNR principles increased the impact on crime outcomes. 
 
o Barnet and Howard (2018) conclude that a common failure of many 
interventions, whether psychoeducational, control oriented or 
deterrence-oriented, is a failure to help people to gain skills needed to 
manage situations differently. They note that “Simply helping people to 
see the impact of their crimes, the consequences of their decisions or 
preventing them from engaging in certain behaviors for a limited 
amount of time, does not appear to help people change behavior in the 
long term. This is supported by behaviour change research more 
generally, which suggests that people need not only the motivation to 
change, but must be capable of that change (i.e., have the right 
knowledge and skills), and have the opportunity to enact that change” 
(Michie, van Stralen, & West, 2011).   
 
• Reinforcing criminal identity is likely to increase the risk of reoffending 
 
o The recidivism literature shows that developing a prosocial, 
noncriminal identity is important to negotiating the hardships and 
setbacks associated with rebuilding one’s life and reintegrating into the 
community following a conviction, while a criminal identity can lead 
people to feel “doomed to deviance” (Maruna, 2001). Barnet et al 
(2018) argue based on their systematic review that “it is possible that 
custodial sanctions, boot camps, mandatory treatment, and drug 
testing or intensive supervision may convey the message to some 
individuals that others believe they are highly likely to reoffend, or that 
a return to crime is almost inevitable”.  
 
• Programmes that are not well implemented are unlikely to work 
 
o Welsh and Rocque’s review (2014) found that the majority of studies 
indicated that drug treatment programmes and specialist drug courts 
have a positive impact and demonstrably reduce reoffending. 
However, they also identified five evaluations that concluded the 
intervention under examination had not just been ineffective, but had 
harmed participants. In the author’s view, this was most likely related 
to poor implementation and adherence to programme design.  
  
23 




Background and model 
 
Commonly used illicit drugs such as heroin, cannabis, opium and MDMA were legal 
in Australia in the first half of the 20th century. These drugs were gradually 
prohibited, but usage continued and in the 1960s, despite prohibition, drug use 
increased as the culture became more socially liberal (Gotsis, Angus, & Roth, 
2016). 
 
Drug policy in Australia is governed by a combination of federal laws and 
regulations, and the National Drug Strategy 2017–2026, which pursues “demand 
reduction, supply reduction and harm reduction”. The dominant strategy for many 
decades has been a policy of criminalising the use and supply of illicit drugs. 
Further control is devolved to states and territories, which also pass their own laws 





• The dominant strategy in Australia for many decades has been a policy of 
criminalising the use and supply of illicit drugs.  
 
• In recent years, some reforms have occurred including:  
 
o Legal decriminalisation of cannabis possession in some States and 
Territories, which have replaced criminal sanctions civil fines. 
  
o In other states, other forms of de facto reform have taken place. 
These generally involve interventions such as diversionary cautions 
or referral to treatment. However, these schemes have strict 
eligibility criteria and can exclude those who may need them most.  
 
o In some places, police have supported harm minimisation 
interventions by, for example, limited unwarranted patrols near 
needle exchanges.  
 
• Research has indicated that drug use in Australia is relatively stable over 
time and cannabis decriminalisation has not increased consumption. 
However, over time the number of civil penalties issued has continued to 
increase, suggesting that police propensity to detect and formally process 
cannabis possession may have increased due to the lower stakes of the 
civil penalty – an effect known as “net widening”.  
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The Queensland Government’s Inquiry into Imprisonment and Recidivism (2020) 
notes that there is some inconsistency between evidence on harm and the 
scheduling of drugs in legislation – noting that ecstasy, a relatively low harm drug, 
is listed in schedule 1, while relatively high harm drugs like fentanyls, are in 
schedule 2.  
 
In recent years, some reform has occurred in drug law and enforcement.  
 
• Legal reform  
 
o South Australia, the Australian Capital Territory and the Northern 
Territory have decriminalised use and possession of cannabis, 
replacing criminal sanction with a system of civil fines.  
 
o No state or territory has undertaken legal reforms for illicit substances 
other than cannabis. Accordingly, many people do still appear in court 
for possession of small quantities of drugs. 
  
o No state or territory has implemented criminal law reforms legalising 
supply-side-related offences. 
 
• Defacto reform  
 
o All jurisdictions that haven’t legally decriminalised cannabis have 
undertaken some kind of de facto reform, including various forms of 
diversionary approaches such as cautions, provision of information, 
referral to treatment, compulsory treatment and compulsory education.  
 
o In most jurisdictions, these types of de facto reforms have also been 
extended to some other illicit drugs.  
 
o All de facto decriminalisation schemes have relatively strict eligibility 
requirements. Typically, these include to admit the offence, not have 
been detected by police more than once or twice, and carry only a 
particular quantity of drug (e.g. 2 grams or less).  Anyone who does not 
meet the requirements (or has exceeded the low limits for past 
referrals) is processed through the usual court mechanism. Such 
eligibility requirements can exclude those most marginalised and/or 
those most in need of diversion into treatment and rehabilitation. De 
jure schemes have fewer eligibility restrictions which increases 
program access and equity.  
 
De facto law enforcement reforms in relation to other harm minimisation 
approaches have also been implemented in some places. In 1988 the 
Commissioner of New South Wales Police discouraged police officers from making 
unwarranted patrols near needle and syringe exchange programmes, in order not 
to discourage drug users from attending. Other police forces subsequently 
introduced similar instructions (Monaghan & Bewley-Taylor, 2013).  
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Hughes et al (2016) concluded that although population drug use rates 
remain stable in Australia, the rates of drug use/possession detections are 
continuing to rise. This means more people who use drugs risk getting charged, 
convicted and imprisoned for minor quantities of drugs.  
 
Outcomes and impact  
 
The research on Australia’s overarching prohibitionist approach is consistent 
in concluding that prohibition contributes to harm rather than minimising it. 
For example:  
 
• The Queensland Government’s Inquiry into Imprisonment and Recidivism 
(2020) concluded that “criminalisation has created significant costs and 
unintended harms. It helped to create an illegal market worth at least $1.6 
billion (with high levels of violence), made the quality of supply uncertain 
(resulting in increased morbidity and mortality), and impeded treatment of 
harmful use”. 
 
• Two studies have been done on the impact of police crackdowns in drug law 
enforcement.  
 
o Wan et al (2014) studied the impact of supplier arrests and seizures of 
heroin, cocaine and amphetamine-type substances over 10 years. 
They found no consistent effects between any of the supply reduction 
measures and police reports of theft, robbery and assault. The findings 
suggest that increases in seizures or supplier arrests indicate 
increased supply in the market making it easier to catch people, rather 
than signalling that a reduction should be expected. There was some 
evidence that ‘very large-scale supply control operations do sometimes 
reduce the availability of illicit drugs for a period’. 
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o Earlier, Maher and Dixon (1999) looked at the impact of ostensibly 
successful crackdowns generating “respectable” arrest and conviction 
rates. However, the authors conclude that “crackdowns, whether 
carried out in the name of law enforcement or quality of life, push 
markets in directions which are highly undesirable.” They reported that 
much sale and consumption simply moved geographically, often to 
more dangerous locations, and that they adopted more dangerous 
transport methods, were less likely to carry clean injecting equipment, 
and increased other unsafe injection practices.   
 
• Research comparing Australian jurisdictions with other countries has 
indicated that punitive approaches do not appear to impact consumption: 
 
o Martin et al (Martin, 2019) found that ecstasy, cocaine, 
methamphetamines and opioids are all significantly more expensive in 
Australia than in other countries, but conclude that this does not 
appear to been a deterrent, since drug use in Australia is relatively 
high. UNODC data suggest Australia has the second-highest 
prevalence of ecstasy use, the equal highest of cocaine, the fourth-
highest of amphetamines and the fourth-highest of prescription 
opioids. 
 
o Degehardt et al. (2008) found that although the proportion of the 
Australian population imprisoned for drugs is substantially lower than 
in the US, “this does not appear to have deterred drug consumption—
the United States consumes more illicit drugs per capita than 
Australia” 
 
One possible explanation for this lack of deterrence is the low probability of 
getting caught. “About 90,000 drug offences are prosecuted each year in Australia 
while an estimated 2680 million drug offences are committed each year (2400 
million cones, 40 million pills, 40 million hits, etc.) or about 1 prosecution per 30,000 
offences; the cocaine rate is about one prosecution for every 110,000 lines of coke” 
(Jiggens, 2013).    
 
Outcomes from cannabis expiation notice schemes seem to be mixed. Under 
this scheme, detected adult offenders can avoid prosecution by paying an expiation 
fee within a set timeframe. Penalties for single offences range from $50 to $150, 
but failure to pay expiation fees could lead to prosecution and the possibility of a 
conviction being recorded. 
 
Evaluations of the scheme’s impact found:  
 
• The proportion of cannabis offences cleared by payment is relatively low, at 
below 50%. Christie and Ali (2009) report that “ one of the most common 
outcomes for offenders who do not clear their CENs by paying the expiation 
fees is prosecution with a conviction being recorded. This has occurred in a 
system that, it could be argued, was designed to remove or reduce that risk 
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of conviction. With many offenders not paying the fees, the absolute numbers 
of convictions being recorded for minor cannabis offences is probably greater 
than if the CEN system had not been introduced.”  
 
• Over time, the number of CENs issued has continued to increase, but 
research shows that cannabis use has remained relatively stable, indicating 
that police propensity to detect and/or formally process these crimes has 
increased.  
 
• Notwithstanding the problems above, the expiation approach has been cost-
effective, reducing enforcement costs without leading to increased cannabis 
use. Eastwood et al (2016) also reviewed the analytical literature on 
decriminalisation’s impact on cannabis use in Australia. They found one 
study reporting a significant increase in cannabis use in states where it has 
been decriminalised, one study demonstrating a decrease in cannabis use 
after decriminalisation, and five studies showing that decriminalisation had no 
significant impact on the prevalence of cannabis use. They conclude that 
“Collectively, this would suggest that at the very least reform of the law and 
the ending of criminal sanctions for cannabis use has no or little impact on 
prevalence” (Eastwood, Fox, & Rosmarin, 2016) 
 





• Canada has allowed medically prescribed cannabis since 2001, and in 
2018 the law was changed to create a fully legal, regulated market for 
recreational use.  
 
• Retail cannabis is now available in all Canadian jurisdictions, with some 
states using government operated retailers and others using licensed 
private providers. 
 
• This change was motivated by a desire to not just decriminalise cannabis 
consumers, but to also remove production and revenue from criminal 
enterprise, giving the government both control over quality assurance, 
and the ability to collect tax on this previously black market.  
  
• It is too early to assess the change’s impact with high confidence, 
however, the data available suggest that:  
 
o After a small initial rise, reported consumption returned to pre-
reform rates and has been relatively stable since.  
 
o Canadians report accessing significantly less cannabis directly 








Background and model   
 
In 2018 the law in Canada was changed to create a fully legal, regulated 
market for recreational use.  
 
Canada’s longstanding cannabis prohibition was first significantly altered in 2001, 
when medically prescribed cannabis was legalised. Various unsuccessful attempts 
were made in the following years at both liberalising and tightening the law, until the 
Cannabis Act was passed in 2018, allowing the creation of a legal, regulated 
market for recreational use.  
 
The Canadian Government emphasised three key goals for this reform:  
o protecting public health 
o protecting young people 
o reducing criminality associated with the illegal market  
 
Reducing criminality associated with the illegal market has a number of motivations. 
The Final Report of the government’s Task Force on Cannabis Legalization and 
Regulation (2016) notes concerns about the proceeds of the illegal cannabis 
trade enriching organized crime groups and funding other types of criminal 
activity, as well as the fact that criminalisation leaves potential tax revenue in 
the black economy rather than with the government; “With decriminalization [as 
opposed to legalisation] the production, distribution and sale of cannabis remain 
criminal activities. Thus, individuals remain subject to the potential dangers of 
untested cannabis. Criminal organizations continue to play the role of producer, 
distributor and seller, thereby increasing risk, particularly to vulnerable populations.”  
 
The key features of the new recreational model in Canada are:  
• Provincial devolution: 
Historically, Canadian provinces have taken their own independent 
approaches to alcohol regulation, and a similar devolved principle was 
applied to cannabis. There are national minimum requirements – individuals 
must be 18 or over, and possession cannot exceed of 30 grams – but 
provinces may place their own further restrictions on possession, cultivation, 
sale and use. Provinces are responsible for developing their own retail 
system, which may be through physical stores and/or federal mail.  
 
• Staged implementation: 
In the first year, the Act only allowed for herbal cannabis and oils to be sold, 
with edibles and concentrates subject to separate regulations, and not going 
on sale until the following year (Government of Canada, 2019)  
 
• Promotion and packaging regulation: 
Products may be branded, but the law prohibits certain activities such as 




Outcomes and impact  
 
Because this law change only occurred in 2018, and was implemented in 
phases, it is too early to robustly assess impact, but there is no evidence that 
the police have faced an increase in issues.  
 
The Transform Drug Policy Foundation note in their one year review of the law that 
“it will inevitably take time for the new system to bed in and for emerging problems 
to be addressed”. Overall, they found that because cannabis regulation was 
devolved to provinces, “a ‘patchwork’ of regulatory models has now emerged 
across the country. Some provinces have been more successful than others 
and many have experienced ‘teething’ issues during early implementation”, 
referring to issues with both preparedness and implementation speed (Transform 
Drug Policy Foundation, 2019). Media coverage has noted specific public criticisms 
of some local implementation programmes, but no formal evaluations are yet 
available.  
 
The details of regulation vary by province/territory (Government of Canada, 2020).  
• The legal age is set at 19 in all but two provinces. 
 
• All provinces allow people to grow cannabis at home for recreational use, 
except Quebec and Manitoba. Where it is allowed, growth is consistently 
limited to four plants per household.  
 
• Retail cannabis is now available in all jurisdictions – eight using government 
operated retailers, and the remaining five licensing private operators. Online 
sales are government operated in all jurisdictions except Saskatchewan and 
Manitoba.  
 
• States are about evenly divided between those that allow use in public and 
those that don’t. States that do generally have limitations in place similar to 
those that govern smoking tobacco in public.  
 
Usage levels are a measure for considering public health implications, although the 
confluence of relevant factors is too complicated to robustly attribute causation to 
any single change. There is data available from the National Cannabis Survey, 
conducted by Statistics Canada from early 2018, although it must be treated with 
caution because:  
 
• The law is too recent for trends to be clear yet, and we would expect to see a 
“novelty blip” at the point of change. The phased rollout further reduces 
comparability of quarterly results.  
 
• People may have been less likely to disclose their use before law change. 
 
• Prior to legalisation, some medical cannabis stores also sold recreationally 
illegally – this informal, quasi-legal grey market may have confused 
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respondents in some areas.  
 
• Sales recorded for medical purposes in July 2019 were lower than in July 
2018, suggesting that at least some of those who previously relied on 
medical documentation were now accessing cannabis on the legal 
recreational market (Government of Canada, 2019).   
 
With these caveats in mind, usage figures can nonetheless be informative. 
Previous national survey data showed a long history of high levels of cannabis 
consumption in Canada, and use has been rising for the preceding 4-5 years 
across almost all age groups (Statistics Canada , 2019). The two waves of data 
available for analysis since the law change:  
 
• suggest use has remained relatively stable since the reform: “After a 
small rise in the first quarter of 2019, reported consumption went back down 
to pre-October 2018 levels in the second quarter.  
 
• indicate a significant decrease in Canadians accessing cannabis directly 
from the illegal market or from friends and family. 
 
• may give some evidence that those who already consumed cannabis prior to 
regulation are consuming more. Data from the first quarter of 2019 indicates 
that the number of occasional users did increase slightly compared to the 
same quarter in 2018. This, too, could potentially be linked to a novelty ‘blip’ 
and changes in survey honesty following the law change. 
 
• recorded an increase in first-time users in the first quarter of 2019, with over 
half of these individuals aged 45 or older. 
 
• Indicate ongoing challenges in encouraging consumers with an established 
supply source towards the legal market – reporting that the average cost of a 
gram of legal cannabis was $10.23 compared to $5.59 for illegal cannabis 
(Statistics Canada, 2019).  
 
There has been no formal analysis yet on the impact the law change has had on 
other crimes or drug driving. Media coverage has generally indicated that police 
have not faced an uptick in problems.1  
 
In terms of cannabis specific offences, police-reported cannabis crime had been 
declining for several years due to being a relatively low police priority. Between 
2017 and 2018, when the law change was made, cannabis related offences fell 
29% overall (although import/export offences rose 22%). Import/export offences 
 





made up 21% of Cannabis Act offences in its first year, followed by possession of 
more than the maximum allowed (18%) (Statistics Canada, 2018).  
 
3.3 Canada (Vancouver harm reduction)  
 
Background and model  
 
In 2003, Vancouver opened the first safe injecting facility in North America, 
called Insite, with a limited exemption from Canada’s drug trafficking and 
possession laws to allow its operation. At the end of the three year pilot 
programme, the exemption was extended, but when the extension ended service 
users brought a court case which resulted in the British Columbia Court of Appeal 
ruling “While users do not use Insite directly to treat addiction, they receive services 
and assistance at Insite which reduce the risk of overdose that is a feature of their 
illness, they avoid risk of being infected or of infecting others by injection and they 
gain access to counselling and consultation that may lead to abstinence and 
rehabilitation. All of this is healthcare” (PHS Community Services Society v Canada 
(Attorney General), 2010). Ultimately, this was affirmed by the Supreme Court of 
Canada in 2010, who ruled that to “close Insite contravened the country's charter of 
rights by threatening the lives of injection drug users” (Small D. , 2012) 
 
Vancouver now has an expanded harm minimisation approach across the city 
including multiple small scale injectable opioid programme sites, pilot drug checking 
service focusing on fentanyl in two sites with “legal authorizations for clients to be in 
possession of controlled substances and a clientele who regularly use opioids, 
stimulants, and other street drugs by injection” (Tupper, 2018) and projects to pilot 
automatic pill dispensing through secure atm-style machines intended to connect 




• In 2003, Vancouver opened North America’s first supervised drug 
consumption facility. It initially operated under a special exemption from 
Canada’s drug laws, and its legal status was affirmed by the Canadian 
Supreme Court in 2010.  
 
• Vancouver police have adopted an organisation-wide policy that treats 
drug use as a public health issue and encourages police to use discretion 
and service referrals to achieve the best outcomes for people who use 
drugs. 
  
• Since it began, there has never been a death at Vancouver’s supervised 
injecting facility. Extensive evaluation has indicated that the facility 
decreases risk of fatal overdose, improves service users’ safe injecting 
practices, increases uptake of addiction treatment, and reduces public 
nuisance issues.  
 
• There is also evidence that relationships between drug users and police 
have improved, and that police now regularly refer people to the safe 












To support these programmes’ success, the Vancouver Police Department 
developed and implemented an organisation-wide drug policy that frames 
drug use as a public health issue and promotes police practices that 
encourage people who inject drugs to access harm reduction services. 
(Landsberg, 2016). In particular, the policy encourages discretionary practices in 
street-level possession and use cases, and supports police referrals to safe 
injection facilities.  
 
Outcomes and impact  
 
Extensive evaluation has indicated that Vancouver’s safe injecting facility 
decreases risk of fatal overdose, improves service users’ safe injecting practices, 
increases uptake of addiction treatment, and reduces public nuisance issues.  
There is also evidence that relationships between drug users and police have 
improved, and that police now regularly refer people to the safe injecting facility.  
 
A number of studies also shed light on the relationship between police and drug 
users in Vancouver:  
 
• In 2001, prior to the reforms described above, a police exercise substantially 
increased police presence throughout the day in the vicinity of a Vancouver 
needle exchange. Researchers found that 27% fewer syringes were 
distributed in the first four weeks of the operation than in the four weeks prior 
(Wood, 2003). However, 9 years later, a qualitative study of policing practices 
in the neighbourhood where Insite is located during the 2010 Winter Olympic 
Games found that, despite higher police presence during this period, it did 
not reduce local drug users’ access to health services or increase injection-
related risk behaviour (Small W. , 2012).  
 
• Police referral procedures have also played an important role. A 2008 study 
of Insite (De Beck, 2008), found that nearly 17 per cent of its clients reported 
being referred to the facility by police. In addition, the individuals the local 
police were referring to Insite were more likely to be engaged in sex work, to 
be frequent cocaine injectors, and to report discarding used syringes in 
public. By referring these particularly high-risk injection drug users to a health 
facility instead of a justice agency, local police help to reduce health harms.  
 
• The authors also note that police referring injection drug users who are more 
likely to discard needles in public spaces to appropriate community services 
also serves to address public nuisance concerns.  
 
Thanks in part to a major resource commitment when Insite was established to 
support robust data collection and research, the safe injecting facility has been 
extensively evaluated using cohort samples of drug users in Vancouver, 
administrative data and topic-specific surveys. Findings in this area can broadly be 
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grouped into those related to the impact on overdoses, access to treatment, 
injecting practices, crime/nuisance, and implementation and targeting.  
 
• Impact on overdoses  
 
o A number of studies have consistently shown that Insite has 
helped to prevent overdose fatalities. Although no overdose at Insite 
has ever resulted in death, nonfatal overdose is fairly common, with 
roughly 13 for every 10,000 injections (Milloy, 2008). In an 18-month 
study in 2004-5, 87% of overdoses were treated just with oxygen. The 
authors concluded overall that Insite plays a role in successfully 
managing overdoses among people who inject drugs, and it is also 
likely that Insite reduces the burden on emergency services that would 
otherwise respond to overdose events.  
 
o Another study estimated how many non-fatal overdoses at Insite would 
have been fatal if they had happened in the community. The author’s 
models suggest that between 8 and 51 deaths were averted in a four 
year period. The number of overdose deaths in the area had averaged 
about 35 over the preceding five years. The authors concluded that the 
care provided in the facility reduces the risk of death and improves 
public health in the area (Kerr, 2006). 
 
o Some critics have suggested that supervised injecting facilities may 
actually lead to more overdoses, if the safe space makes people feel 
more comfortable with the risk of taking a higher dose. An evaluation 
surveying more than 1,000 Insite users over two years tested this 
theory, but found that those who were at Insite for the majority of their 
usage were not more likely to overdose than those who mostly used 
outside the service (Milloy, 2008).  
 
o Qualitative research with 50 service users also supports these 
findings-  people who used Insite reported that it addresses many of 
the environmental factors that drive the high rate of overdose among 
people who inject drugs. In particular, giving people the time to 
carefully and safely inject without rushing is noted as a key way in 
which InSite reduces overdose risk (Kerr, Small, Moore, & Wood, 
2007).  
 
• Impact on access to treatment  
 
o The Canadian cohort study found that attendance at Insite was 
associated with increased referral to addiction care centres, 
uptake of detox treatment and uptake of methadone maintenance 
(Wood E. , 2006). Contact with Insite’s addictions counsellor further 
significantly increased a person’s chances of enrolling in detox. 
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o In the year after Insite opened, there was a 33% increase in detox 
service use, compared to the year prior. Moreover, Insite clients who 
entered detox were 1.6 times more likely to enroll in methadone 
treatment and 3.7 times more likely to enroll in other forms of addiction 
treatment. People who entered detox also visited Insite less frequently 
in the month after enrolling in detox services than in the month prior to 
enrolment (Wood, Tyndall, Zhang, Montaner, & Kerr, 2007).  
 
o Criticism that safe injecting facilities may make people in recovery 
more likely to relapse was also tested in a study. However, no change 
was found in rates of relapse into injection drug use among former 
users in the year after Insite opened compared to the year before, and 
fewer people started binge drug use. The authors conclude that the 
facility’s benefits have not been offset by negative effects on drug use 
patterns in the area (Kerr T. , 2006) 
 
o People’s access to other medical treatment also improved. A 
qualitative study of 50 service users found that nurses at InSite 
regularly provide care for injection-related infections and frequently 
connect drug users with off-site medical treatment by supplying 
referrals and arranging transportation. Service users reported that it 
was easier to get care for infections there than in conventional care 
settings because Insite nurses are experienced in working with drug 
users and because the facility is open late at night. Additionally, the 
authors note that if scaled this type of care has the potential to reduce 
emergency room use and hospitalization among local injection drug 
users (Small W. , 2008). 
 
• Impact on injecting practices  
 
A large number of studies have looked at Insite’s impact on injecting 
practices. They have consistently found: 
 
o Reduced needle sharing:  
 
After adjustment for relevant socio-demographic and drug use 
characteristics, use of the facility was associated with a marked 
reduction in syringe sharing (Kerr T. , 2005) These findings are 
supported by earlier results suggesting that attendance at Insite 
appears to reduce syringe sharing specifically in HIV risk situations 
(HIV+ people lending needles or HIV- people borrowing them), and 
analysis of Insite data combined with a similar study in Spain 
concluded that regular safe injection facility users reduce their 
likelihood of sharing syringes by 69% (Molloy, 2009).  
 
o Improved knowledge and practice of other safety measures:  
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The education provided at Insite has also been found to positively 
impact people’s use of safe injecting practices. A study comparing 
those who consistently visited Insite (for 25% or more of their 
injections) and those who used the facility less consistently found that 
consistent Insite attenders were substantially more likely to use sterile 
water, swab injection sites, dispose of syringes safely, and cook or 
filter their drugs. They were also less likely to rush during injections or 
share syringes. The authors conclude that InSite is helping to reduce 
some of the health risks associated with unsafe injecting (Stolts, 2007).  
 
A 2006 survey, (Petrar, 2007) found that 75% of Insite Users 
reported injecting more safely as a result of visiting Insite. 
Qualitative research with 50 InSite clients supports these findings 
(Fast, 2008), with many people reporting that they did not know about 
the benefits of cleaning the skin with an alcohol swab prior to injecting, 
inserting the syringe bevel-side up, or other measures they could be 
taking to minimize health risks. Regular Insite users reported that they 
learned about these practices from nurses in a way that felt safe, 
supportive and unhurried. Importantly, study participants told 
researchers that the overall environment at the facility encouraged 
them to adopt the safer practices and to make a habit of using 
them both within and outside of the facility.  
 
A small number of research participants did report that they had not 
received safer injecting education at the facility, indicating that Insite 
may not be meeting the educational needs of everyone who injects 
drugs there. Those people who use the facility often are more likely to 
interact regularly with nurses and receive educational messages that 
help protect health.  
 
o Reduced public injecting:  
 
A study of those Insite users who also continue to inject publicly was 
published in 2007. The results showed that those still injecting publicly 
were 3 times more likely to be homeless compared to other Insite 
users, and also 1.6 times more likely to require help injecting (a 
practice that is not permitted at Insite). People who continue to inject in 
public told researchers that the waiting times limit their use of the 
facility. The authors conclude that increasing availability through a 
program expansion may further help to reduce persistent risk 
behaviours and address community concerns about ongoing levels of 
public drug use, and that the restriction against assisting with injections 
at Insite may pose a barrier to use by some people who inject drugs 
(McKnight, et al., 2007).  
 
Fairburn et al also note in their qualitative research that in many cases, 
the first time a woman uses an injection drug, someone else— usually 
an older male— injects the drug for her. By learning how to inject 
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themselves, women rely less on men and gain more control over the 
circumstances of their own drug use. They are then more likely to 
practise safer habits when injecting, such as using clean needles 
(Fairburn, Small, Shannon, Wood, & Kerr, 2008).  
 
• Impact on crime, nuisance and the community   
 
o A rigorous quasi-experimental study found that the number of 
people injecting in public, number of publicly discarded syringes, 
and amount of injection related litter all declined significantly in 
the 12 weeks after Insite opened, compared to the weeks before 
(Wood, et al., 2004).   
 
o More broadly, crime rates in the year before Insite opened were 
compared with crime rates in the year after, using Police data on drug 
trafficking, assaults, robberies, vehicle break-ins, and thefts. 
Researchers found no statistically significant changes in rates of drug 
trafficking, assaults, or robberies, and a drop in vehicle break-ins and 
thefts. The results of this study provide evidence that Insite’s presence  
has not contributed to an increase in drug-related crime in surrounding 
neighbourhoods. 
 
• Implementation and service user targeting  
 
o Due to its extensive evaluation, much can be learned about 
implementation and service user targeting from the Insite model.  
o Multiple cohort and survey samples have shown that InSite is attracting 
those at highest risk, as is intended (Wood, et al., 2005) (Wood, et al., 
2006). The researchers concluded that the facility was successfully 
attracting:  
 
▪ people who are at elevated risk of blood-borne disease or 
infection 
▪ people at elevated risk of overdose  
▪ people who were using publicly or unsafely disposing of syringes  
▪ Marginalised people including homeless people, sex workers, 
younger people and indigenous people.  
 
o A survey of over 1000 service users also identifies some of the most 
common obstacles to using the service. These were most frequently 
travel time to Insite, the facility’s limited operating hours, and the 






Background and model 
 
Denmark has pursued harm-reduction policies such as opioid substitution 
treatment (OST) and needle exchange programmes for many years, but 
politicians and health authorities initially opposed drug consumption rooms (Ministry 
of the Interior and Health, 2003) (Ministry of the Interior and Health, 2010). 
However, in 2011, in an act of civil disobedience, Danish NGOs started two mobile 
drug consumption rooms in retired ambulances, staffed by volunteer nurses and 
doctors (Ege, 2012), and the next year Denmark passed legislation to allow 
municipalities to establish drug consumption rooms.  
 
The amendment to Denmark’s law on psychedelic substances had three stated 
intentions:  
• to reduce the number of overdose deaths,  
 
• to improve life situations for people who use drugs by connecting them to the 
healthcare system, treatment facilities and social services,  
 
• to reduce the nuisance of public drug taking to surrounding neighbourhoods 





• Since a law change in 2011, Denmark now has five Drug Consumption 
Rooms across three municipalities.  
 
• Overdose deaths in Denmark have been falling since consumption rooms 
were introduced. Evaluations indicate that DCR’s have reduced the 
number of overdose deaths in the cities that have them.  
 
• There is also evidence from evaluations of the Copenhagen facility that 
crime, violence and publicly discarded syringes have all decreased in the 
area.  
 
• Research has highlighted the important role consumption rooms have 
played in helping people access health, social and addiction services.  
 
• Research on police attitudes also suggests that the advent of 
decriminalization zones around consumption rooms has caused more 
police to view drug users as people in need of police protection rather than 









The bill amending the law provides that “within the vicinity of the DCRs, police 
will not prosecute people who are over the age of 18 years, who possess 
drugs for their own use, and who have a prolonged use of and addiction to 
illicit drugs” This can be seen as a form of de facto decriminalisation of drug use, 
since possession remains an offence, but in practice the law is not fully enforced.  
 
The key features of the Danish DCR model are summarised here from Keppel et al 
(2019):   
• Consumption rooms follow two delivery models: 
o Integrated units, typically part of a shelter with additional services such 
as counselling, laundry and shower facilities, or a health clinic.  
o Mobile unit, with relatively limited space, primarily only functioning as a 
hygienic, safe place for injecting.  
 
• DCRs are financed by the municipalities and managed by NGOs2.  
 
• All DCRs are staffed with registered nurses or nursing aides, who work in a 
team alongside social workers and social educators. All staff members have 
advanced first aid training and are trained in the effects and side effects of 
the most commonly consumed drugs, but no additional formal training is 
required to work at a DCR. The healthcare professionals are mainly 
responsible for intervention and treatment in cases of severe intoxication.  
 
• To access DCRs, clients must:  
o register, create an alias that will be used for future entry, and agree to 
house rules. 
o accept that staff will intervene if they overdose 
o indicate at every entry what drug they plan to consume 
o not be a minor or pregnant 
o not deal or trade within the facility 
o no client is allowed to provide assistance to peers 
 
In addition to providing safe, clean space for consumption, DCRs also provide 
information on drug ingredients and potency, refer clients to a variety of treatment 
and health services, and may also issue clients with Naloxone. The staff address 
barriers to care for injection-related injuries, provide low-threshold nursing attention 
on site, and connect with off-site medical service (Small, Wood, Lloyd-Smith, 
Tyndall, & Kerr, 2008). 
 
Outcomes and impact 
 
There are now five DCRs, spread across three municipalities in Denmark, all 
of them in permanent locations with integrated services except for one mobile unit 
in Copenhagen. By 2016, within five years of the law change, there were 3600 
service users registered at DCRs (Toth, Tegner, Lauridsen, & Kappel, 2016).  
 




The Danish ministerial evaluation of DCRs is not available in English, but Kappel et 
al (2016) report that it indicates “DCRs in Denmark has had an effect on 
reducing the number of deaths by overdose in the cities that have 
implemented the DCR programme”. Although we cannot confidently attribute 
causation, it is noteworthy that Denmark’s overdose deaths peaked in 2011, the 
year the DCRs commenced, and have been declining since. Other impacts have 
been reported in the media – news articles (such as Boffey, 2013 and Busby, 2018) 
on the Copenhagen DCRs have reported that:   
 
o Year on year, burglaries in the wider area are down by about 3%, theft from 
vehicles and violence down about 5%, and possession of weapons also 
down. 
 
o Up to 10,000 syringes used to be picked up off the streets of Vesterbro every 
week before the room opened. Since the launch of the room, the quantity of 
drug paraphernalia collected from gutters, playgrounds, stairwells and 
doorways in the area has halved. 
 
Their research concluded that the “humanizing approach of DCR staff, combined 
with the provision of facilities and tools for drug consumption, appear to promote a 
sentiment of social acceptance among DCR clients” and noted that this was 
consistent with other studies of DCRs (eg (Rance & Fraser, 2011). They further 
found that the approach empowered the DCR clients towards feeling more “like 
citizens rather than scummy junkies”, and concluded that this empowerment is in 
fact “the most important feature of DCRs… which ultimately paves the way for both 
the successful prevention of overdoses, as well as for steering clients towards 
utilizing both social and health services, including drug rehabilitation facilities.” 
 
Fieldwork for Kappel et al’s study also observed that the trust forged between the 
staff and clients was evidenced in their willingness to heed staff’s advice on being 
cautious with their intake, and attribute this as a success of the service. They also 
note that DCRs appear to function as bridges to other health and social services, 
including drug treatment, but that it is difficult to measure impact because people 
use aliases to access the DCR, and are then need to follow up the referral 
themselves.   
 
The model is also reported to have had an impact on policing practices. According 
to qualitative research by Kammersgaard (2019) “decriminalization zones that were 
established with the DCRs in 2012 enabled the police to abstain from traditional 
drug law enforcement techniques that focus on use reduction through punishment 
and the confiscation of illegal substances. Instead the police were able to direct 
their attention to the wider harm experienced by people who use drugs”.  
Kammersgaard further suggests that this policy change led to police viewing 
people who use drugs primarily as people in need of police protection rather 




3.5 Netherlands (cannabis ‘coffee shop’ market)  
 
 
Background and model  
 
In the early 1970s, two government committees on drug law (Hulsman, 1971 and 
Baan, 1972) recommended attempting to separate cannabis from the wider drug 
scene, to reduce the extent to which young people who experimented with 
cannabis were exposed to more harmful substances.  
 
Since 1971, cannabis has been decriminalised for personal use, and the 
Ministry of Health has had primary responsibility for drug policy. A further law 
change in 1977 sanctioned tolerant policing practices that had emerged as informal 
policy in the previous decade, giving authorities the ability to creatively interpret the 
new legislation in their local areas. Public prosecutors subsequently deprioritised 
small scale cannabis offences, focusing almost exclusively on large operations and 
harder drugs (De Kort, 1995).  
 
‘Coffee shops’, where people could buy cannabis more or less free from the risk 
police enforcement, emerged as an unintended consequence of this change, and 
the Government responded with restraint, applying a pre-existing but informal set of 
tolerance criteria: that coffee shops must only sell small quantities, and not serve 
young people, advertise or cause nuisance.  However, due to this unclear legal 
status, enforcement was inconsistent, with some places raided while others were 





• Cannabis has been decriminalised for personal use since 1971. The 
current day ‘coffee shop’ model has developed through a dialogue 
between informal police tolerance policies and legislative/regulatory 
reform.  
 
• Today, coffee shops may sell cannabis as long as they are licensed and 
adhere to a range of regulations, including limits on the volume that can be 
traded, a minimum age of 18, and not selling alcohol or contributing to 
public nuisance.  
 
• The consumer side of this model has been largely successful, and 
cannabis use in the Netherlands is about average for Europe despite its 
laws being significantly more liberal than most.  
 
• However, because the law only permits and regulates small scale, 
consumer transactions, the cultivation and wholesale supply to coffee 
shops remains unregulated and criminal enterprise is significantly involved.  
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The number of coffee shops continued to grow and eventually in 1991 formal 
regulation was brought in which: 
• Set a minimum age of 18 
• Decreased the maximum transaction amount to 5 grams per person per day 
• Limited daily trade to 500g 
These regulations have been strengthened over time, for example tightening 
restrictions on premises licensees, and giving local municipalities the power to 
close down coffee shop’s deemed to cause a public nuisance.  
 
In 2012, the government piloted a new approach, known as the ‘weed club pass’. 
This required coffee shops to operate on a small membership-only model, and only 
residents of the Netherlands could become members (Aanwijzing Opiumwet, 2012) 
(although, as discussed below, this was not successful and the pilot has not been 
rolled out more widely). 
 
Outcomes and impact  
 
There is no evidence that the relatively free availability of cannabis has led to 
substantial increases in consumption. Despite having significantly more liberal 
laws than its neighbours, cannabis use in the Netherlands is on par with the 
European average (Grund & Breeksema, 2017).  
 
However, while the consumer side of the coffee shop model has been largely 
successful, important lessons can be drawn from the Netherlands’ 
experience of what is termed the “back door problem”. The regulated coffee 
shop model means sales of small quantities (ie, retail to consumers – the ‘front 
door’) is exempt from prosecution, but cultivating larger quantities for supply (ie, 
wholesale supply to coffee shops – the ‘back door’) remains illegal (De Kort, 1995). 
This came about, according to former Prime Minister Van Agt, because ‘there was 
no parliamentary majority for decriminalising the supply of cannabis or other drugs 
in 1976, and the Dutch government did not want to risk diplomatic or economic 
problems with neighbouring countries and the international community’.  
 
The compromise reached gave consumers safe access in regulated environments, 
certainly lowering harms to them, but the vast majority of research agrees that the 
fact cultivation and supply to coffee shops is not regulated is the main source 
of the negative side effects currently seen in the Netherlands, particularly the 
involvement of organised crime and the lack of quality control. Investment in 
criminal enforcement has not been effective at removing these problems. At the 
same time, the Dutch government has felt limited in their ability to regulate the back 
door because of the potential diplomatic and economic consequences (Grund & 
Breeksema, 2017). 
 
Through the 1990s and early 2000s periodic police crackdowns on suppliers and 
home growers had the unanticipated consequence of significantly increasing 
criminal organisations’ involvement in cannabis cultivation (Belackova, Maalste, 
Zabransky, & Grund, 2015). This problem has arguably been exacerbated by the 
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fact that the Ministry of Health has primary responsibility for drug policy, and do not 
see this type of commercial regulation or criminal law enforcement as their role.  
 
The 2012 pilot in southern provinces, of clubs restricted to small memberships of 
only Dutch residents, was not found to be very successful. Much of the evaluation 
literature is not available in English, but Grund and Breeksema summarise it: 
“Nuisance from street drug sales and feelings of lack of security increased (SSC 
Onderzoek en Informatie, 2012). Local consumers refused to register at coffee 
shops, citing privacy concerns (Wouters and Korf, 2011; Nijkampand Bieleman, 
2012) and many regulars abandoned the shops, resorting to illegal markets instead 
(Maalsté and Hebben, 2012).” Consequently, soon after the pilot was introduced, 
the requirement that shops be limited-membership only was abolished, while the 
requirement to only serve Dutch residents was devolved to local municipalities, 
many of which do not enforce it (Opstelten, 2012). 
 
 
3.6 Netherlands (harm minimisation)  
 
Background and model  
 
The Netherlands tried unsuccessfully to dismantle the organised crime groups 
importing heroin in the 1970s and 80s, but its prevalence continued to grow. As 
street level policing crack downs drove heroin dealing indoors, many local 
municipalities supported tolerating these so-called “street addresses” as a way of 




• The Netherlands has developed a comprehensive health-based harm 
minimisation approach, with many of their most notable policy 
developments arising from informal or experimental practices that were 
subsequently codified by the government. Needle exchanges, safe 
injecting facilities and heroin assisted treatment are all examples of this.  
 
• The Netherlands has very low rates of problem drug use, and arrests for 
minor possession are extremely rare.  
 
• Drug users in the Netherlands also tend to use safer practices (for 
example, a very low proportion of opiate users inject), and this has led to 
relatively high survival rates and longer life expectancy for people who use 
heroin in the Netherlands.  
 
• Due to substantial investment in sheltered housing, integrated drug 
treatment, public mental health care, services for the homeless and 
criminal justice interventions, most problematic drug users now live in 
supported housing where they receive welfare and treatment. 
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In some cities, the police, drug services, urban planners, and neighbourhood 
organisations actively collaborated with dealers and proprietors of street 
addresses, with an unwritten understanding that they would be tolerated as 
long as they sold only consumer amounts and did not advertise, cause nuisance or 
serve young people. This lasted until a crackdown in the 1990s closed street 
addresses again, causing the heroin and crack cocaine market and users to return 
to the streets (Grund & Breeksema, 2017).  
 
The Netherlands has developed a comprehensive health-based harm 
minimisation approach, with the most notable policy developments coming 
out of informal or experimental practices that were subsequently codified by 
the government. For example:   
• Needle distribution began informally in the 1970s, and continued to grow 
through grass roots organising, until official needle and syringe exchange 
programmes were introduced (Blok, 2008) (Grund, et al., 1992). By 2012 
there were 150 needle exchange programmes in the Netherlands. 
(EMCDDA, 2012). 
• As early as 1974, off-the-record drug injection rooms were available in two 
Amsterdam drop-in centres, and one in a church basement in Rotterdam 
began in 1982 (Blok, 2008). These activist projects laid the groundwork for 
the official safe consumption facilities that opened in most large Dutch cities 
1995. By 2012 there were 37 drug consumption rooms across the country, 
targeting injectors and smokers (Schatz & Nougier, 2012)(EMCDDA, 2012). 
• Heroin Assisted Treatment was introduced in 1996 as a scientific trial and, 
after a favourable evaluation, was registered as a legal medication for 
‘chronic, treatment-resistant heroin-dependent patients’ in 2006 (Blanken, et 
al., 2010) (Fischer, et al., 2007).  
 
An official agreement with the public prosecution service ensures that anyone 
possessing illicit drugs at an official drug-testing service will not be arrested or 
prosecuted (EMCDDA, 2017) 
 
Outcomes and impact  
 
The largely tolerant, harm-minimisation focussed approach to drugs in the 
Netherlands has not given rise to high prevalence.  
• The Netherlands has the lowest level of problem drug use in the EU (Van 
Laar & Van Ooyen-Houben, 2009) 
• The overall prevalence of drug use in the general population is below the EU 
and USA averages(ECMDDA, 2012; Van Laar et al., 2014).  
 
Arrests and criminal records for use or minor possession are extremely rare in the 
Netherlands compared to other European states (3 per 1,000 users, compared to 
44 per 1,000 users in Austria) (Room, 2008).  
 
The research also indicates a number of other ways in which Dutch drug policy has 
contributed to reducing harms. Notably, the Netherlands has one of the lowest 
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rates of injecting amongst opiate users – only about 7% of all people in 
treatment for heroin dependence were or are injecting users. This has served to 
reduce Dutch opiate and crack cocaine users’ risks of both overdose and HIV, 
which has contributed to relatively high survival rates of people who use heroin 
(Grund & Breeksema, 2017). Treatment for heroin dependence increasingly 
includes elements of geriatric care, and the EMCDDA recently complimented the 
Netherlands for pioneering senior citizens homes for the aging group of heroin 
consumers (EMCDDA, 2015).  
 
The Netherlands also provides important lessons in the unintended consequences 
of intensive law enforcement. Research suggests that both of the major policing 
crackdowns attempted in the last 50 years led to increasing harms:  
• Schreuder and Broex  (1998) found that policing crackdowns in the 70s did 
not stop the escalation in heroin. Instead, they argue that along with other 
environmental trends, stringent policing contributed to pushing street scenes 
out of the city centre, diffusing heroin into more working-class 
neighbourhoods. 
 
• A large body of research suggests that as street addresses were closed by 
a crackdown in the 90s, drug users were pushed into a much less 
favourable risk environment. Without the protective environment and social 
control of the street addresses, people smoking cocaine in the streets 
became increasingly prone to its negative side effects, and the street market 
scene became larger, more volatile, and more harmful to the people in it  
(Blanken, Barendregt, & Zuidmulder, 1999).  
 
Finally, the success of the Dutch approach has relied on government investing 
significant resources in a comprehensive and integrated harm reduction, 
treatment and social support system targeting people with drug problems, the 
homeless and chronic psychiatric patients (Grund & Breeksema, Drug Policy in the 
Netherlands, 2017).  Since 2006, coordinated investments have been made in: 
• sheltered housing 
• integrated drug treatment 
• public mental health care 
• services for the homeless, and  
• criminal justice interventions  
 
Consequently, most problematic street drug users now live in sheltered or 
supported housing where they receive welfare, medical care and tailored drug 
treatment, or consume their drugs in on-site drug consumption rooms (Schatz, 
Schiffer, & Kools, 2010). Those who continue to cause nuisance or engage in crime 
are subjected to various criminal justice interventions, including compulsory 








Background and model  
 
At the end of the 1990s, Portugal was noted for high rates of problematic drug use 
and heroin market. This led to significant increases in infectious diseases, 
particularly HIV and AIDS, and drug related deaths with a peak of 369 in 1999 
(Hughes & Stevens, 2010) (Van Het Loo & Van Beusekom, 2002). 
 
In 1998 the Commission for a National Anti-Drug Strategy brought together legal, 
medical, and social professionals and recommended that decriminalisation of drug 
use and possession would allow the government to focus on prevention, harm 
reduction, treatment, and helping people to maintain their social connections 
(Domoslawski, 2011). Law enforcement and health experts viewed criminalisation 
as part of the problem rather than the solution because people with addictions were 






o In 2001, following expert medical and social strategic advice, Portugal 
decriminalised the purchase, possession and use of all illicit drugs.  
 
o The change went beyond depenalisation, which removes custodial 
sentencing, but did not amount to full legalisation, as the production, 
manufacture and large-scale distribution of illicit drugs remain a criminal 
offence. 
 
o Studies have generally found that the change did not significantly 
increase consumption or drug prices. Moreover, analysis estimates that 
decriminalisation has decreased the social costs of drug use by 18%. 
 
o Initially, decriminalisation had a clear direct impact on prison populations 
in Portugal, with fewer people incarcerated and fewer incarcerated 
people reporting drug use. Incarceration rates began to rise again in 
2008, although the profile of incarcerated offenders is now different and it 
is likely other external trends contributed to this.  
 
o There is some evidence of “net-widening” leading to increasingly low 
level offenders being brought before commissions. This is an important 
implementation lesson in ensuring laws are explicitly designed to prevent 
mission creep.  
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In 2001, Portugal decriminalised the purchase, possession and use of all 
illicit drugs. The change went beyond depenalisation, which removes custodial 
sentencing as an option for low-level drug offenders, but did not amount to 
legalisation, as the production, manufacture and large-scale distribution of 
illicit drugs remain a criminal offence.  
• Low-level offenders are now dealt with administratively by an informal 
‘Dissuasion Commission’, which determines an appropriate non-custodial 
sanction. The Commission’s work regionally, and their purpose is not to 
punish the offender but to encourage treatment and rehabilitation. 
  
• The commission determine whether the person suffers from addiction or not, 
and then choose from a range of consequences.  
 
• If the person suffers from addiction, commission is not able to mandate 
treatment but can suspend a penalty on the condition that an offender agrees 
to get treatment. 
 
• Commissions may also impose fines or restrictions (from one month to three 
years) on people, depending on a range of factors including the type of drug, 
whether it was used in public, and how often the person uses.  
 
• The Commissions come under the Ministry of Health rather than Ministry of 
Justice and include a treatment professional, social worker and lawyer, and 
are supported by a range of agencies such as treatment, health, 
employment, child protection, social services and schools.   
 
Investments in drug treatment, harm reduction and social reintegration were also 
expanded at the same time. Crucially, the Government moved away from 
providing harm reduction interventions on a small scale based on local risk 
reduction and short-term aid, to a systematic approach across the whole 
country (Leite, 2019). 
 
Outcomes and impact  
 
In 2017, 11,329 people were involved in commissions, a new high watermark and 
an 80% increase over the period of a decade. In 2017, around 10% of those before 
commissions were classed as addicts (SICAD, 2019). For those classed as addicts, 
the most common ruling is a suspension to allow the perpetrator to undertake 
treatment. For those not considered addicted, the majority receive a provisional 
suspension. Between 2007 and 2012, only 4-6% appeared before a commission 
again, and 88% of those only registered one relapse in a year (SICAD, 2013). 
 
Studies have generally found little impact on usage or drug prices:  
 
• Reviews of the Portuguese experience of decriminalising all drugs have 
not found evidence of an increase in drug use (Greenwald, 2009) 
(Hughes & Stevens, 2010) Depending on the study examined, there was 
either no increase or only a very small increase in adult drug usage. 
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• In line with this, Felix and Portugal (2017) found that prices for cocaine and 
opiates did not decrease following decriminalization. They conclude that 
“drug decriminalization seems to have caused no harm through lower illicit 
drugs prices, which would lead to higher drug usage and dependence. This 
evidence contrasts with the commonly held belief that drug decriminalization 
would necessarily lead to a dramatic increase in usage rates. 
 
Studies have indicated a number of benefits in terms of drug harms and costs:  
 
• An ex-post analysis of Portugal's decriminalisation of all drugs estimated that 
the total social cost of drug use decreased 18 per cent (Goncalves, 
Lourenco, & Nogueira da Silva, 2015). This was mainly driven by reductions 
in indirect health costs (29 per cent), non-health related indirect costs (24 per 
cent) and non-health related direct costs including the criminal justice system 
(17 per cent). There was an increase in direct health costs of 9 per cent 
associated with providing prevention, treatment and harm reduction services. 
 
• Greenwald (2009) and Hughes & Stevens (2010) drew similar conclusions. 
“The reforms did lead to a reduction in drug-related harms (both problematic 
drug use and youth drug use declined), and criminal justice system costs: 
While small increases in drug use were reported by Portuguese adults, the 
regional context of this trend suggests that they were not produced solely by 
the 2001 decriminalization. We would argue that they are less important than 
the major reductions seen in opiate-related deaths and infections, as well as 
reductions in young people’s drug use. The Portuguese evidence suggests 
that combining the removal of criminal penalties with the use of alternative 
therapeutic responses to dependent drug users offers several advantages. It 
can reduce the burden of drug law enforcement on the criminal justice 
system, while also reducing problematic drug use.” (Hughes & Stevens 2010, 
p.1018)   
 
• An economic analysis of the effects concluded that the Portuguese 
approach was not harmful and contributed to a reduction in seizures of 
heroin and cocaine, number of drug offences,  drug-related deaths and 
the incidence of HIV among drug addicts (Felix, Portugal, & Tavares, 
2017). 
 
• Opioid substitution treatments and injecting rooms have been tried in many 
jurisdictions and these approaches have been associated with reduced 
overdose hospitalisations and deaths, public injecting and discarding of 
needles (EMCDDA 2018). 
   
Initially at least, it was possible to discern a direct impact of decriminalisation on 
incarceration rates in Portugal. Between 2000 and 2008 there was a fall in the 
imprisonment rate from 126 per 100,000 to 102, and the number of offenders 
who reported using heroin before entering prison also fell from 27 per cent in 
2001 to 13 per cent in 2007 (Hughes and Stevens, 2010). Since 2008, 
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however, there has been a notable rise in imprisonment again, and rates 
are now comparable to those before the reform. Again, the extant English 
language literature does not seem to offer an explanation for this trend, although 
the Council of Europe report on European prisons 2005-2015 indicates that 
during that period, at least, the proportion of prisoners sentenced for assault and 
battery as well as for sexual offences increased, while the proportion serving 
sentences for homicide, robbery, theft and drug offences decreased. It may 
therefore be that other trends in some combination of crime, detection, 
enforcement and sentencing have contributed to re-filling Portugal’s prisons with 
a different profile of offender.  
 
The Portuguese experience offers a number of important implementation 
lessons:  
• Laqueur (2014) highlights the way in which Commissions are increasingly 
being required to deal with younger, non-addicted people for cannabis-
related offences, which amounted to 76% of cases in 2009, and notes that 
such cases create a strain on scarce resources. This gradual increase in 
young, non-addicted people coming before commissions for small amounts 
of cannabis appears to be a similar phenomenon to the “net widening” effect 
seen in Australian cannabis expiation schemes, and underscores the need to 
consider ways to prevent this mission-creep in law enforcement, such as 
explicitly excluding certain substances or groups from enforcement 
measures, or by fully legalising and regulating trade.   
 
• Strain on resources has also been identified by others as a factor impeding 
the work of the Commissions (Pinto, 2010) . An evaluation of the 2008-2013 
action plan identified that a lack of quorum was responsible for delays in the 
system (SICAD, 2013; Laqueur, 2014). Pinto also highlighted that people 
being referred for treatment were often already undergoing treatment.  
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4. Other international examples of note 
  
• Uruguay is the first country in the world to create a legal, regulated market 
for adult cannabis use with the explicit goal of undermining the illegal drug 
market and severing cannabis revenue from those who also sell harder 
drugs. The law allows people to grow their own cannabis, purchase it 
commercially, and join a cannabis club that cultivates and distributes to 
members (Leite, 2019)   
 
• Mexico: In 2009, Mexican Federal Government enacted "narcomenudeo" 
reforms decriminalizing possession of small amounts of drugs, delegating 
prosecution of retail drug sales to the state courts, and mandating treatment 
diversion for habitual drug users. There is not a large body of evaluative work 
on the impact of this change. Two studies from Tijuana are informative, but 
impacts on a wider range of health and social outcomes, and in other parts of 
the country, are not known:  
o A mixed methods study in Tijuana found that “Narratives underscored 
the law’s irrelevance to PWID; 699 (98%) saw police practice as 
generally inconsistent with formal law. Instead of treatment diversion, 
police encounters were associated with risk behaviors, including 
syringe sharing” (Beletsky, et al., 2015).  
o A study that looked at policing practice in Tijuana found that the 
change did not appear to have significantly shifted drug law 
enforcement practices, and other factors, such as electoral cycles, 
were more strongly associated with arrest volumes (Arredondo, et al., 
2018).  
 
• Germany’s Federal Constitutional Court ruled in 1994 that drug addiction is 
not a crime, and neither is possession of small amounts for personal use, 
although production, distribution and acquisition remain illegal. Threshold 
quantities for the decriminalisation of personal possession have been defined 
by the courts over time. In 2000 a new narcotic law was passed to allow safe 
injecting facilities. German research into heroin-assisted treatment in the 
2000s yielded positive results, and heroin-assisted treatment has been part 
of mandatory health insurance there since 2009.  
 
• USA: There is a growing trend amongst US states towards liberalising state 
drug laws, despite tension with the federal law characterised by the war on 
drugs.  
o Recreational cannabis is now legal in fifteen states, and ballot 
measures have also been used to ease restrictions on harder drugs in 
some. Most notably, in the 2020 US election Oregon decriminalised 
personal possession of small quantities of drugs including cocaine, 
heroin, methamphetamines and psychedelics.  
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o Most drug law reforms in the US are relatively recent and their impact 
cannot be fully assessed yet, but the following findings are available 
from those jurisdictions that were relatively early reformers:  
▪ Cannabis  
• Cannabis decriminalization showed improvements in risk 
areas for teenagers, declines in possession arrests, and 
reduction in illegal markets in 5 states, but true public 
health effects of cannabis legalisation cannot yet be 
assessed, because it has only been implemented within 
the past 5 years and cannabis remains illegal under US 
federal law (Hall & Lynskey, 2016) (Hall et al., 2019)  
 
• Law reform in California has also enabled automatic 
expungement of past marijuana convictions and an 
estimated 218,000 individuals are due to benefit as a 
result. 
 
• Colorado: the contraband cannabis industry still flourishes 
in Colorado (Stuart, 2014) and Washington (Kleiman et al., 
2015). The Washington data showed that more than a 
year after legalization, illegal sources still accounted for an 
estimated 28% of cannabis sold in the state. 
 
• FBI data from Colorado and Washington show that crime 
clearance rates — the frequency of crimes being solved 
by police — increased for both violent and property crimes 
after legalization (Makin, et al., 2018). 
 
• Oakland, California and Massachusetts have both 
considered social equity for people and communities 
disproportionately impacted by cannabis law enforcement 
in the design of their legalisation programmes. In Oakland, 
half of the licenses to grow and distribute cannabis are 
reserved for people who earn less than 80% of the 
average income, have been charged with a cannabis 
offense in the last 20 years, or have lived for a decade or 
more in a neighbourhood with disproportionately high 
cannabis arrests. There is a similar programme in 
Massachusetts. Elsewhere, state taxes ensure a portion of 
the revenue generated from legal sales is allocated back 
into such disproportionately impacted communities (Nicol, 
2019).  
 
• National: In a national survey of US students, Palamar et 
al. (2014) found that 10% of non-using students intended 
to use cannabis if made legal, and that 18% of users 
expected to increase their use upon legalization of the 
drug (Palamar, Ompad, & Petkova, 2014). 
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▪ Other drugs  
 
• By 2015, 30 states had Naloxone programmes, covering 
654 police departments. Rando et al, found that following 
these police officer Naloxone programs, the number of 
opioid overdose deaths decreased (Rando, Broering, 
Olson, Marco, & Evans, 2015).  
 
• A process evaluation of Seattle’s Law Enforcement 
Assisted Diversion (LEAD) programme, a pre-booking 
diversion scheme for narcotics and sex work charges, 
highlighted the importance of ensuring reforms are 
implemented and supported by front line police. They 
found examples in Seattle’s programme where officers 
were reluctant to divert people who use drugs through 
LEAD because they felt the programmes ‘enabled’ 
addiction. Beckett emphasises the importance of ensuring 
buy-in from all levels of police forces, not just the 
leadership (Beckett, 2014).  
 
• Many studies in the US have looked at the costs and 
benefits of treatment programmes.  
o A California study of treatment outcomes found a 
benefit to cost ratio of 7 to 1, largely attributable to 
reductions in subsequent criminal activity (Ettner, et 
al., 2005).  
o A literature review of 18 benefit-cost studies found 
that benefits exceeded costs, with benefit–cost 
ratios of 1.6 to 26 (Cartwright, 2000).  
o A Minnesota study found benefit–cost ratios for 
treatment and recovery services of between 2.4 and 
16.1. For prevention and early intervention services, 
the study found benefit–cost ratios of 0.2 to 20.4 




5.  Summary of key themes 
 
5.1 Overview of criminalisation and harm minimisation  
 
Research on drug criminalisation generally indicates that criminal sanctions 
for drug use or possession tend to exacerbate harm or undermine efforts at 
harm minimisation. For example:  
• Injection safety:  
Studies looking at barriers to using a new needle for every injection in large, 
diverse urban settings have consistently found that fear of law enforcement 
encounters is associated with people:  
o Sharing syringe and injection equipment (Wagner, 2010) (Wagner, 
Simon-Freeman, & Bluthenthal, 2013) (Bluthenthal, 1999) (Wood, 
2017) (Pollini, 2008) (Flath, 2017) 
o not accessing new needles, from reduced exchange program 
participation (Wood, 2017) (Beletsky, 2014) (Bluthenthal, 1997) (Davis, 
2005) 
o feeling reluctant to carry new needles (Flath, 2017) (Sarang, Rhodes, 
& Platt, 2008) (Grund, 1995) 
 
• Treatment access:  
When evidence-based and delivered well, treatment is known to be a cost 
effective means of reducing drug harms.  
o A 2015 study in England used estimates of opioid use in the general 
population, the extent of treatment provision, and the number of deaths 
related to opioid use, to develop a counterfactual model which 
estimated that treatment prevented 880 excess opioid-related deaths 
each year between 2008 and 2011 (White, et al., 2015).  
o Evidence from the US looking at the cost-benefit ratios of treatment 
programmes consistently show that their benefits reflect a large return 
on investment. A study of California treatment outcomes found a 
benefit to cost ratio of 7 to 1, largely attributed to reductions in 
subsequent criminal activity (Ettner, et al., 2005). This is consistent 
with an earlier literature review of 18 benefit-cost studies, which found 
that benefits exceeded costs, with benefit–cost ratios of 1.6 to 26 
(Cartwright, 2000).    
 
Considering this, it is important to ask what impact prohibition has on 
treatment engagement. An international survey of drug users found that 
those from countries with a strong prohibition-based drug policy reported a 
far greater propensity to seek help following the introduction of more 
permissive policies (Benfer, et al., 2018). The main reason for the change in 
help-seeking behaviour cited was the reduced fear of criminal sanctions.  
 
• Incarceration: 
A meta-analysis of studies from six countries found that after imprisonment, 
drug users were at three to eight times more risk of drug-related death in the 
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first two weeks after release, and remained elevated for a further two weeks 
(Merrall, et al., 2010). 
 
• Justice system strain: 
Decriminalisation reduces the demands on the criminal justice system, 
through less demand on police, courts and prisons. For example, total law 
enforcement costs in California dropped from $17 million in the first half of 
1975 (before decriminalisation) to $4.4 million in the first half of 1976 (after 
decriminalisation). Such savings can contribute towards replacing criminal 
intervention with well-resourced social and treatment intervention instead.   
 
Additionally, research from New Zealand estimated that more than half of the 
revenue from all drug trafficking is reinvested in criminal activity, and that 
around 20-28% of this funds other organised crime activities such as 
extortion, fraud, pornography, illegal poaching and weapons trafficking 
(McFadden Consultancy, 2016). 
 
• Social integration: 
Decriminalisation improves employment prospects and relationships with 
significant others for those detected with drugs, and evidence from a number 
of countries shows that decriminalisation can lead to improved social 
outcomes. For example, individuals who avoid a criminal record are less 
likely to drop out of school early, be sacked or to be denied a job. They are 
also less likely to have fights with their partners, family or friends or to be 
evicted from their accommodation as a result of their police encounter (Drug 
Policy Modelling Programme, 2016).   
 
Moreover, research indicates that decriminalisation does not lead to 
significant increases in drug use or other crimes (Babor, et al., 2010).   
 
• Decriminalisation has no or very small effects on rates of drug use. Research 
from across the globe has consistently found that decriminalisation is not 
associated with significant increases in drug use.  
 
• In instances where just cannabis has been decriminalised it has not led to 
increases in use of other drugs such as ecstasy or heroin. 
 
• Research has shown that decriminalisation does not lead to increases in 
crime through perceptions of weaker laws. People who do not receive a 
criminal record are much less likely to engage in future crime or have 
subsequent contact with the criminal justice system, even when previous 
offending history is taken into account. There is also no evidence that 
decriminalisation will lead to other types of crime, such as supply or drug-
related crime. 
 
Within a legalised system, there are different purchaser/end-user regulatory 
options including, for example, age and place of use restrictions like those 
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that most jurisdictions currently use for alcohol. From least to most strict, these 




Regulation focuses on standard product descriptions and 
labelling. Where appropriate, food and beverage legislation 
(dealing with packaging, sell by dates, ingredients etc.) may 




Licensee is responsible for restricting sales on the basis of 
age, intoxication and hours of opening. Licence 
infringements may be sanctioned by a sliding scale of fines, 
loss of licence, or even criminal penalties. Licensees can be 
held partially or wholly liable for how their customers 
behave, similar to the licensed premises model applying to 
the on-premises sale of alcohol. Various controls exist over 
the venue and (in particular) the licensee. 
Licensed 
sales model 
May put various combinations of regulatory controls in 
place to manage the vendor, the supply outlet, the product 
and the purchaser. These controls may be supported by 
changes to police, customs, trading standards, and health 
and safety policies and practices, similar to the off-premises 
sale of alcohol. 
Pharmacy 
sales model 
Pharmacists are trained and licensed to dispense 
prescriptions, although they cannot write them. They can 
also sell certain generally lower risk medical drugs from 
behind the counter of licensed pharmacy venues, usually 
with conditions such as buyer age, level of intoxication, 
quantity requested, or case-specific concerns relating to 
potential misuse. Pharmacists are overseen by regulatory 
legislation, managed by various agencies and are subject 
to a clearly defined enforcement infrastructure. 
Prescription 
model 
The most tightly controlled and enforced drug supply model 
- drugs are prescribed to a user by a qualified and licensed 
medical practitioner, and dispensed by either a licensed 
practitioner or pharmacist from a licensed pharmacy or 
other designated outlet. The process is controlled by a 
range of legislation, regulatory structures and enforcement 
bodies, which guide, oversee and police the prescribing 
doctors and dispensing pharmacists. They also help 
determine which drugs are available, in what form, where, 
and under what criteria. 
 
summarised from Rolles, 2010 
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One negative consequence of decriminalisation that has been reported in 
research from Australia is ‘net widening’. Net widening occurs when more 
people are sanctioned after a reform than before, due to the greater ease with 
which police can process minor drug offences. The extent of this depends on the 
specific choice of policy design and how the reform is implemented (for example, 
whether the consequences for non-compliance are more severe than the original 
offence; the extent of police discretion) (Bryan, Del Bono, & Pudney, 2011).  
 
 
5.2 Drug consumption rooms  
 
To reduce harm and prevent overdoses, many countries including Denmark, 
Switzerland, Germany, Spain, Norway, Australia and Canada have established 
drug consumption rooms or safe injecting facilities over the last 30 years . 
Drug consumption rooms are typically professionally supervised healthcare facilities 
where drug users can use drugs in safer and more hygienic conditions. As of 2018 
there were over 90 DCRs in over 60 cities across 10 different countries, with 
several more jurisdictions working towards them (EMCDAA, 2018).  
 
A growing body of scientific evidence shows that consumption rooms have 
an impact on both improving health and reducing death by overdose among 
clients who use these facilities (Bravo, De la Fuente, Brugal, Barrio, & Domingo-
Salvany, 2009) (DeBeck, et al., 2011) (Kinnard, Howe, Kerr, & Marshall, 2011). For 
people who use drugs, unsafe drug intake often involves unhygienic or incorrect 
injecting, which cause both injury and infection. A systematic review found that 
supervised consumption at a facility reduces the risk of fatal overdose and disease 
transmission (Pardo, Caulkins, & Kilmer, 2018).  
 
Several qualitative studies highlight the benefits of DCRs, noting that they can 
address various contextual risks associated with public injecting by:  
 
• enabling safer injection practices (Kerr, Small, Moore, & Wood, 2007), 
• providing refuge from street-based crime (Fairburn, Small, Shannon, Wood, 
& Kerr, 2008),  
• mediating and facilitating access to healthcare and social resources (McNeil 
& Small, 2014) and  
• delivering education regarding safer injection practices which is more likely to 
be accepted among clients than it would be from other sources (Fast, 2008).  
 
However, as noted above regarding criminalisation, the success of these 
services relies on people’s willingness to engage with them. Fear of 
apprehension by the law can be a significant deterrent to accessing services, so to 
be effective, DCRs should be accompanied by support from policing to ensure 
service users are not criminalised, and that police actively refer people who use 
drugs to the service.  
Evidence on consumption rooms’ impact at a population level is sparse, but 
some evidence from ecological studies suggests that, where coverage is 
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adequate, drug consumption rooms may contribute to reducing drug-related 
deaths at city level (Poschadel, Hoger, Schnitzler, & Schreckenberger, 2003) 
(Marshall, Milloy, Wood, Montaner, & Kerr, 2011). A study in Sydney showed that 
there were fewer emergency service call-outs related to overdoses at the times the 
safe injecting site was open (Salmon, Van Beek, Kaldor, & Maher, 2010). 
5.3 Cannabis law reform  
 
For decades, research on the impact of cannabis decriminalization has shown that, 
in a variety of jurisdictions in Australia, Europe, Canada and the United States, 
decriminalization does not cause a significant increase in consumer demand 
or ease of access.  
 
• Data from four Canadian cities showed that under prohibition, cannabis users 
generally, even in times of easy access, moderate their cannabis use such 
that it does not interfere with their lives or lead to adverse health 
consequences. These patterns appear to continue under decriminalization 
(Duff, et al., 2012).  
 
• The literature on depenalisation of cannabis possession in various states of 
the United States, the Netherlands, Portugal and Australian states finds that 
reducing penalties has either no or only small effects on prevalence of use 
(Home Office, 2014) (Hughes, 2016) (MacCoun, 2010). 
 
• Bryan et al (2013) found there was no evidence that decriminalisation of 
limited cultivation in South Australia and Alaska substantially changed 
consumption. 
 
• At the same time, decriminalization decreases related social problems (such 
as criminal records and their impact for people) as well as enforcement and 
judicial costs (see, for example: (Single, 1989) (Lenton, et al., 2000) (Room, 
2008). 
 
In relation to young people specifically, a recent review of 38 countries shows no 
significant increase in cannabis use amongst adolescents living in liberalised states 
(Stevens, 2019). Consistent with the results of previous researchers, the most 
comprehensive empirical study to date found: 
  
• there was no evidence that the legalization of medical marijuana encourages 
marijuana use among youth.  
 
• Moreover, the estimates showed that marijuana use among youth may 
actually decline after legalization for recreational purposes (Anderson, 
Hansen, Rees, & Sabia, 2019).  
 
• Some of the evidence suggests legalisation may reduce underage 
consumption in some instances, due to fewer illegal suppliers.  
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There is also some evidence that liberalising cannabis laws causes some people to 
substitute away from higher harm drugs such as opioids or alcohol. In US states 
that have legalised medicinal cannabis, there is early evidence of some people 
substituting from opioids to cannabis, and lower attendant health burdens:  
 
• death certificate analysis showed that states with medical cannabis laws had 
lower opioid analgesic overdose mortality rates compared with states without 
such laws (Bachhuber, Saloner, & Cunningham, 2014).  
 
• This persisted when excluding intentional overdose deaths (ie, suicide), 
suggesting that medical cannabis laws are associated with lower opioid 
analgesic overdose mortality among individuals using opioid analgesics for 
medical indications.  
 
• Similarly, the association between medical cannabis laws and lower opioid 
analgesic overdose mortality rates persisted when including all deaths 
related to heroin, even if no opioid analgesic was present, indicating that 
lower rates of opioid analgesic overdose mortality were not offset by higher 
rates of heroin overdose mortality (Bachhuber, Saloner, & Cunningham, 
2014). 
 
• A study of substance use trends amongst US college students in the ten 
years ending 2018 found that recreational cannabis legalisation was linked to 
decreased binge drinking among students age 21 and older. Recreational 
marijuana legalisation was also associated with increased sedative misuse 
among minors (Alley, Kerr, & Bae, 2020).  
 
• Dragone et al. (2019) estimated that cannabis legalisation increased 
cannabis consumption by about 2.5 percentage points, a decrease in alcohol 
consumption of 2 points and a decrease in other drug consumption of about 
0.5 points. This change in consumption was associated with a change in 
criminal behaviour, with reductions in rape of between 15 and 30 per cent 
and theft of between 10 and 20 per cent.   
 
• In their review of the evidence Anderson and Rees (2014) find that "studies 
based on clearly defined natural experiments generally support the 
hypothesis that marijuana and alcohol are substitutes." Increasing the 
drinking age seems to result in more marijuana consumption, for instance, 
and pot smoking drops off sharply at age 21, "suggesting that young adults 
treat alcohol and marijuana as substitutes." This supports other findings that 
legalizing marijuana for medical use has been associated with a drop in beer 
sales and a decrease in heavy drinking.  
 
• Earlier research found that enacting medical marijuana laws is associated 
with a 13 percent drop in traffic fatalities. They posit that this effect is likely 
due to a combination of the fact that marijuana impairs driving ability much 
less dramatically than alcohol does, and the fact that alcohol is more likely to 
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be consumed outside the home, resulting in more driving under its influence 
(Anderson, Hansen, & Rees, 2013). 
There is some evidence that prohibition of cannabis has led to the advent of 
synthetic cannabinoids, which have been formulated to mimic the effects of 
natural cannabis but have much greater harms.  The incentive for this 
innovation arises because of their benefits in a prohibited market place: “They are 
easy to purchase, relatively inexpensive, produce a more potent high and don’t emit 
the typical marijuana scent. And, they are much harder to detect in the urine or 
blood than marijuana. Legalisation is likely to shift users from synthetic cannabis 
back to natural cannabis. Regulation would also reduce contamination of natural 
cannabis” (White C. , 2018).  
 
• In 2013 alone, 150 new cannabinoids were identified and these new 
synthetic drugs have been linked to poisonings, hospitalisations and deaths. 
Serious illnesses due to cannabis are exceedingly rare, while those due to 
synthetic cannabinoid use are becoming more common, and clusters of 
synthetic cannabinoid overdose are associated with the newest drugs 
(Bannister et al. 2015).  
 
• A recent study of Australian drug harms (Bonomo, et al., 2019) ranked the 
harm to users from synthetic cannabis as more than twice that from natural 
cannabis. An American study estimated synthetic cannabinoids were 30 
times more likely to harm the user (White, 2017).  
 
There is less in the published literature on implementation issues, but it is worth 
noting that several health policy organizations in Canada and abroad have warned 
against the perils that industry lobbying may present for protecting the public’s 
health in cannabis law reform. One proposal for mitigating this issue is for a legal 
market to be operated by the state: 
 
• “A not-for-profit cannabis authority would maintain a singular mission of 
protecting the public’s health. It would serve this mission by supplying safe 
product to serve only the existing demand for cannabis. There would be no 
intent, or provision of incentive or encouragement of any kind to increase 
use among cannabis users or to induce nonusers to start using cannabis. 
Given the primacy of a public health mission, a long-term objective might 
actually be to reduce use by individuals and prevalence in the general 
population. The Authority would provide and promote evidence-based 
information on the low-risk use of cannabis, and actually encourage and 
support people who wanted to stop or reduce their cannabis use” (De 
Vallaer, 2017). 
 
5.4 Reform for other drugs  
 
As experience of significant law reform regarding harder drugs than cannabis is 
relatively recent and not yet widespread, there is less research evidence available 
to draw from. However, the overall trend of the literature on drug law 
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enforcement consistently indicates that increases in punitive or prohibitionist 
approaches are generally associated with increased harms and, conversely, 
that many harms can be ameliorated when the law, and/or its enforcement, is 
relaxed.  
 
• Studies using data from Florida, New York and Portugal consistently show 
that escalations in drug enforcement are accompanied by property and 
violent crime rates increasing, relative to what they would have been 
(Benson, 2009). 
 
• Effectively removing mandatory minimum sentences for people convicted of 
a range of felony drug charges, and increasing eligibility for diversion to 
treatment led to a 35 percent rise in the rate of diversion of eligible 
defendants to treatment in New York. Although the use of diversion varied 
significantly among the city’s five boroughs, it was associated with reduced 
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7. ANNEX: TABLE OF REFORMS  
 
Jurisdiction Year Reform 
Colorado 2012 Legalised possession and supply of cannabis 
Washington 2012 Legalised possession and supply of cannabis 
Oregon 2014 
Legalised possession and supply of cannabis. 
Decriminalised possession of other drugs.  
Alaska 2014 Legalised possession and supply of cannabis 
California 2018 Legalised possession and supply of cannabis 
Nevada 2016 Legalised possession and supply of cannabis 
Massachusetts 2016 Legalised possession and supply of cannabis 
Maine 2016 Legalised possession and supply of cannabis 
Michigan 2018 Legalised possession and supply of cannabis 
Illinois 2019 Legalised possession and supply of cannabis 
Washington DC 2015 Legalised possession and supply of cannabis 
Guam 2019 Legalised possession and supply of cannabis 
15 other US states  Decriminalised use/possession of cannabis 
Canada 2018 
Legalised possession and supply of cannabis. Medically 
supervised heroin injecting.  
Uruguay 2013 Legalised possession and supply of cannabis 
Bolivia 2009 Legalised supply and posession of coca 
Spain 2001 
Legalised consumption, growing and cannabis social 
clubs, but commercial production and sale remain 
illegal.  
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Netherlands 1974 
Retail but not wholesale cannabis sales ‘de facto’ 
allowed through outlets. Posession of small quantities of 
other drugs (eg half a gram of cocain) is generally 
unenforced. Medically supervised heroin injecting.  
Chile 2005 
All private drug use/possession is unpunished. 
Thresholds between trafficking and personal use 
determined by a judge.  
Croatia 2012 
All drug use/ possession decriminalised. Drug use itself 
is not regulated by the law, but administrative 
regulations apply for public usage.  
Czech Republic 2009 
All drug use/possession decriminalised, but financial 
fines can apply.  
Mexico 2009 
All drug use/possession decriminalised, however 
quantities are ambiguous. In 2018 the Supreme Court 
ruled a ban on the use of cannabis was unconstitutional.  
Peru 2003 
Possession of small quantities of cannabis, cocaine, 
opium and MDMA are not punishable. However, police 
practices may not always reflect this.  
Portugal 2001 All drug use/ possession decriminalised 
Costa Rica  Use/posession of cannabis de facto decriminalised 
Ecuador  Decriminalised use/possession of cannabis  
Estonia  Decriminalised use/possession of cannabis  
France 2018 
Depenalised use/possession of cannabis to 200 euro 
fine  
Georgia 2018 
Legal possession and consumption, but not sale, of 
cannabis through a constitutional court decision 
Germany  
Authorities not required to prosecute possession of 
minor amounts 
India  
Illegal but exceptions are made for selling and 
consuming bhang 
Jamaica 2015 
Decriminalised use/possession of cannabis. Legalised 
use for religious purposes 
71 
Luxembourg 2001 Decriminalised use/possession of cannabis 
Paraguay 1988 Decriminalised use/possession of cannabis 
South Africa 2018 
A constitutional court decision legalised cannabis 
consumption by adults in private places 
Switzerland 1990s 
Decriminalised use/posession of cannabis. Medically 
supervised heroin injecting.  
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